

(12) Oversættelse af ændret
europæisk patentskriftPatent- og
Varemærkestyrelsen

- (51) Int.Cl.: **A 61 K 38/17 (2006.01)**
C 07 K 14/475 (2006.01) **A 61 K 39/395 (2006.01)**
C 07 K 14/515 (2006.01) **A 61 P 35/00 (2006.01)**
C 07 K 16/18 (2006.01)
- (45) Oversættelsen bekendtgjort den: **2019-01-21**
- (80) Dato for Den Europæiske Patentmyndigheds
bekendtgørelse om opretholdelse af patentet i ændret form: **2018-10-31**
- (86) Europæisk ansøgning nr.: **07819170.7**
- (86) Europæisk indleveringsdag: **2007-10-19**
- (87) Den europæiske ansøgnings publiceringsdag: **2009-07-29**
- (86) International ansøgning nr.: **EP2007009105**
- (87) Internationalt publikationsnr.: **WO2008046649**
- (30) Prioritet: **2006-10-20 EP 06022070**
- (84) Designerede stater: **AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR**
- (73) Patenthaver: **Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts, Im Neuenheimer Feld 280, 69120 Heidelberg, Tyskland**
- (72) Opfinder: **KAZANSKAYA, Olga, Im Erlenweg 22, 69124 Heidelberg, Tyskland**
Niehrs, Christof, Neuenheimer Landstrasse 34, 69120 Heidelberg, Tyskland
OKAWARA, Bisei, Friedrich-Ebert-Anlage 56, 69117 Heidelberg, Tyskland
- (74) Fuldmægtig i Danmark: **Plougmann Vingtoft A/S, Strandvejen 70, 2900 Hellerup, Danmark**
- (54) Benævnelse: **Rspondiner som modulatorer af angiogenese og vaskulogenese**
- (56) Fremdragne publikationer:
EP-A1- 2 997 975
WO-A2-01/77169
WO-A2-2005/040418
EASWARAN V. ET AL: 'Beta-Catenin regulates vascular endothelial growth factor expression in colon cancer'
CANCER RESEARCH vol. 63, 15 June 2003, page 3153, XP3145
AOKI M. ET AL: 'R-spondin3 is required for mouse placental development' DEVELOPMENTAL BIOLOGY vol. 301, 10 August 2006, pages 218 - 226
GOODWIN A.M. ET AL: 'Wnt signaling in the vasculature' ANGIOGENESIS vol. 5, 2002, pages 1 - 9
WO-A-2005/040418
US-A1- 2005 054 829
US-A1- 2005 059 073
US-A1- 2006 149 049

DK/EP 2081586 T4

DESCRIPTION

1. INTRODUCTION

[0001] The present invention relates to the use of Rspordin polypeptides, particularly Rspordin2 (Rspo2) or Rspordin3 (Rspo3) or Rspordin nucleic acids. The invention is based on the demonstration that Rspo3 and Rspo2 are angiogenesis promoters, and the identification of Rspo2 and 3 as positive regulators of vascular endothelial growth factor (VEGF). These results indicate a major role for Rspordin, particularly Rspo3 and/or Rspo2 in the signalling system during angiogenesis. The invention also relates to the use of Rspordin3 antagonists, in the treatment of conditions, including cancer, by modulating angiogenesis and/or vasculogenesis.

2. BACKGROUND OF THE INVENTION

[0002] The Rspordin protein family is conserved among vertebrates and consists of the four related members Rspordin1-4 (Rspo1-4) (Chen et al., 2002, Mol. Biol. Rep. 29, 287-292, who called Rspo3 hPWTsR; Kamata et al., 2004, Biochim. Biophys. Acta.1676, 51-62; Kazanskaya et al., 2004, Dev. Cell 7, 525-534; Kim et al., 2005, Science 309, 1256-1259; Kim et al., 2006, Cell Cycle 5, 23-26; Nam et al., 2006, J. Biol. Chem. 281, 13247-13257). Human Rspo1-4 were also described as Stem Cell Growth Factor Like Polypeptides, which are able to promote proliferation of hematopoietic stem cells (WO 01/77169; WO 01/07611) or may be used in the treatment of a variety of diseases (US 2006/0149049, US 2005/0059073) that can be alleviated by increased or reduced angiogenesis (US 2005/054829). They were also designated as FUTRIN1-4 and identified as modulators of the Wnt signalling pathway (WO 2005/040418). The content of these documents is herein incorporated by reference and the amino acid and nucleic sequences of Rspordin 1-4 disclosed therein are specifically included herein.

[0003] The Rspo genes encode secreted proteins which can activate Wnt/b-catenin signalling, and Rspo2 promotes myogenesis via the Wnt/b-catenin signalling pathway in Xenopus (Kazanskaya et al., 2004, Dev. Cell 7, 525-534). Rspordin genes are widely coexpressed with Wnt genes in many regions during embryonic development, and Rspordin expression is positively regulated by Wnt signals (Kamata et al., 2004, Biochim. Biophys. Acta.1676, 51-62; Kazanskaya et al., 2004, Dev. Cell 7, 525-534). Furthermore, it was reported that secreted human Rspo1 promotes proliferation of intestinal epithelium through stabilizing of b-catenin (Kim et al., 2005 Science 309, 1256-9). Mutation of mouse Rspo3 results in embryonic lethality and induces severe defects in the development of the placenta (Aoki et al., Dev Biol. 2007 301(1):218-26). However, no effect on blood vessel development was reported in this mutant model and, in contrast to the results disclosed herein, the embryos appeared to show no sign of haemorrhage, therefore there was no suggestion before the present invention that

Rspondin, in particular Rspondin 2 or 3, played a significant role in angiogenesis and/or vasculogenesis.

[0004] Angiogenesis is likely to be regulated by polypeptide growth factors. Several polypeptides with *in vitro* endothelial cell growth promoting activity have been identified. Examples include acidic and basic fibroblastic growth factor, VEGF and placental growth factor.

[0005] VEGF is a key factor in vasculogenesis and angiogenesis and its signalling pathway an important target for pharmacological intervention (Ferrara 2005, Oncology 3:11-6; Rosen 2005, Oncologist 10:382-91).

3. SUMMARY OF THE INVENTION

[0006] The present invention relates to the use of Rspondin polypeptides or Rspondin nucleic acids. The invention is based on the demonstration that Rspo3 and Rspo2 are vasculogenesis and angiogenesis promoters. Further, they induce endothelial cell growth and have been identified as positive regulators of VEGF.

[0007] The results indicate a major role for Rspondins polypeptides, particularly Rspo2 and/or Rspo3 in the signalling system during angiogenesis and/or vasculogenesis.

[0008] Rspondin polypeptides (e.g. Rspo2 or Rspo3), Rspondin nucleic acids, and agonists of Rspondin, are suitable in the treatment of conditions wherein said treatment involves promoting angiogenesis and/or vasculogenesis

[0009] Antagonists of Rspondin polypeptides (e.g. of Rspo2 or Rspo3) or of Rspondin nucleic acids, are suitable in the treatment of conditions wherein said treatment involves inhibiting angiogenesis and/or vasculogenesis.

[0010] Disclosed herein is the use of Rspondin polypeptides, Rspondin nucleic acids and regulators or effectors or modulators of Rspondin for diagnostic applications, particularly for the diagnosis or monitoring of angiogenesis- and/or vasculogenesis-associated processes, conditions and disorders.

[0011] Further disclosed are cells and transgenic non-human animals exhibiting modified, e.g. increased or decreased Rspondin, particularly Rspo2 and/or Rspo3, expression.

[0012] Rspondin polypeptides and Rspondin nucleic acids and cells or transgenic animals may be used in screening procedures in order to identify and/or characterize effectors of angiogenesis and/or vasculogenesis.

4. BRIEF DESCRIPTION OF THE FIGURES

[0013]

FIG. 1: *Rspo3* is necessary for the blood vessel cell development in *Xenopus tropicalis*. *Xenopus tropicalis* embryos were injected at the 4 cell stage with control or *Rspo3* morpholino antisense oligonucleotides (Mo) as indicated. Embryos were fixed at tailbud stage and *in situ* hybridization for markers of blood (α-globin, SCL, Mead et al., 1998, Development 125, 2611-2620) or forming blood vessels (msr, Devic et al., Mech Dev. 1996; 59,129-40) was carried out. Note the expansion of blood markers and inhibition of msr in *Rspo3* Mo-treated embryos.

FIG. 2: Demonstration of the specificity of *Rspo3* morpholino antisense oligonucleotides. *Xenopus tropicalis* embryos were injected in two ventral blastomeres at the 4-8 cells stage with *Rspo3* morpholino antisense oligonucleotides (Mo) with and without *Xenopus laevis* *Rspo2* mRNA as indicated. At gastrula stage (stage 10) ventral marginal zones (VMZ) were excised and cultured until sibling embryos reached stage 28. VMZs were fixed and processed for whole mount *in situ* hybridization for the blood marker α-globin. Note rescue of *Rspo3* Mo-induced expansion of α-globin by *Rspo2* mRNA. This rescue shows the specificity of the morpholino phenotype.

FIG. 3: *Rspo3* is necessary and sufficient for promoting blood vessel cell development in *Xenopus tropicalis*. *Xenopus tropicalis* embryos were injected at the 4 cells stage with control or *Rspo3* morpholino antisense oligonucleotides (Mo) or *Xenopus laevis* *Rspo2* mRNA as indicated. At gastrula stage the ventral marginal zone was excised and cultivated in isolation until stage 28. RT-PCR analysis was carried out for the indicated marker genes. H4, histone 4 for normalization. -RT, minus reverse transcriptase control. Note that Mo inhibition of *Rspo3* inhibits blood vessel marker VEGF and msr expression and induces the blood markers α-globin and SCL.

FIG. 4: Expression of *Rspo3* in vasculature of mouse embryos. *In situ* hybridisation of *Rspo3* in E 10.5 mouse embryo is shown. Arrowheads point to expression in embryonic blood vessels.

FIG. 5: Targeted mutagenesis of murine *Rspo3*. (A) Genomic structure of *Rspo3* and targeting vector used for homologous recombination in ES cells. (B) Targeted allele before and (C) after elimination of neomycin selectable marker gene using Flp recombinase.

FIG. 6: *Rspo3* mutant mice show internal bleeding. Photographs of wild-type (wt) and *Rspo3*-/- embryos (mutant) mice at E10.5. Note haemorrhages in the mutant mouse, indicative of failure of blood vessel formation.

FIG. 7: *Rspo3* mutant mice show reduced blood vessel formation. Wild-type (wt) and *Rspo3*-/- (mutant) yolk sacs of E 10.5 embryos are shown. Note pale yolk sac in mutant.

FIG. 8: *Rspo3* mutant mice lose VEGF expression. Whole mount *in situ* hybridization for VEGF is shown in placentas of wild-type (wt) and *Rspo3*-/-embryos (mutant) of E 9.5.

FIG. 9: *Rspo2* induces angiogenesis in the chicken chorioallantoic membrane (CAM) assay.

FIG. 10: Rspo2 induces tube formation in endothelial cells. Control or *Xenopus laevis* Rspo2 conditioned medium was applied to human endothelial cells (HDMEC) for 5 days. Note induction of morphogenesis indicative of tube formation, as is characteristic during angiogenesis.

FIG. 11: Rspo2 induces endothelial cell growth. Control or *Xenopus laevis* Rspo2 conditioned medium or 0.5ng/ml VEGF was applied to human endothelial cells (HUVEC) for 2 days and cell proliferation was assayed using a commercial kit (Roche).

5. DESCRIPTION OF THE INVENTION

5.1 1 Definitions

[0014] As used herein the term '**Rspordin polypeptides**' according to the present invention refers to members of the Rspordin family which may be derived from mammalian or other vertebrate organisms. The Rspordin protein family consists of the four related members Rspordin1-4 (Rspo1-4).

[0015] Preferably, the Rspordin polypeptide is a human Rspordin, e.g. human Rspordin1, 2, 3 or 4. More preferably, the Rspordin polypeptide is an Rspordin2 or 3 polypeptide, particularly a human Rspordin2 or 3 polypeptide. The amino acid sequences of human Rspordin polypeptides 1, 2, 3 and 4 are shown in WO 2005/040418, the content of which is herein incorporated by reference. Further examples of Rspordin polypeptides are Rspordins from *Xenopus*, e.g. *Xenopus tropicalis* and *Xenopus laevis* or from *Mus musculus*.

[0016] Further sequences for human Rspordin nucleic acid and amino acid sequences are as follows: Human Rspordin 1 nucleic acid sequence (NM_001038633, SEQ ID NO: 16), amino acid sequence (ABA54597, SEQ ID NO: 17), human Rspordin 2 nucleic acid sequence (NM_178565, SEQ ID NO: 18), amino acid sequence (NP_848660, SEQ ID NO: 19), human Rspordin 3 nucleic acid sequence (NM_032784, SEQ ID NO: 20), amino acid sequence (NP_116173, SEQ ID NO: 21), human Rspordin 4 nucleic acid sequence (NM_001029871, SEQ ID NO: 22), amino acid sequence (NP_001025042, SEQ ID NO: 23).

[0017] Rspordin polypeptides are further defined herein as polypeptides that show at least 40%, preferably at least 60%, more preferably at least 80%, at least 90%, at least 95%, at least 98% or at least 99% sequence identity at the amino acid level to the respective human Rspordin polypeptide over its entire length (Kazanskaya et al., 2004, Dev. Cell 7, 525-534). Further, Rspordin polypeptides according to the invention are preferably characterized as having at least one biological activity selected from

1. i induction of angiogenesis in the CAM assay,
2. ii induction of tube formation in endothelial cells,
3. iii induction of endothelial cell growth, particularly growth of human endothelial cells, and
4. iv induction of VEGF expression.

[0018] The term 'polypeptide' includes to full-length proteins, proteinaceous molecules, fragments of proteins, fusion proteins, peptides, oligopeptides, variants, derivatives, analogs or functional equivalents thereof.

[0019] The term '**functionally equivalent to Rspordin**' as used herein refers to a protein which induces angiogenesis and/or VEGF expression. The gene product itself may contain deletions, additions or substitutions of amino acid residues within the Rspordin, e.g. Rspo2 or Rpo3 sequence, which result in a silent change thus retaining significant signal transducing capacity thus producing a functionally equivalent Rspordin. Such amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipatic nature of the residues involved. For example, negatively charged amino acids include aspartic acid and glutamic acid; positively charged amino acids include lysine and arginine; amino acids with uncharged polar head groups having similar hydrophilicity values include the following: leucine, isoleucine, valine; glycine, alanine; asparagine, glutamine; serine, threonine; phenylalanine, tyrosine.

[0020] As used herein the term "**Rspordin nucleic acid**" refers to nucleic acid sequences that encode members of the Rspordin family and which may be derived from mammalian or other vertebrate organisms. Preferably, the Rspordin nucleic acid encodes a human Rspordin, e.g. human Rspordin1, 2, 3 or 4. More preferably, the Rspordin nucleic acid encodes an Rspordin2 or 3 polypeptide, particularly it encodes a human Rspordin2 or 3 polypeptide. The nucleic acid sequences of human Rspordin 1, 2, 3 and 4 are shown in WO 2005/040418, the content of which is herein incorporated by reference. Further examples of Rspordin nucleic acids are those which encode the Rspordins from *Xenopus*, e.g. *Xenopus tropicalis* and *Xenopus laevis* or from *Mus musculus*.

Rspordin nucleic acids are further defined herein as molecules selected from

1. (a) nucleic acid molecules encoding Rspordin polypeptides, e.g. a human Rspordin, particularly Rspo2 and/or Rspo3,
2. (b) nucleic acid molecules which hybridize under stringent conditions to a nucleic acid molecule of (a) and/or a nucleic acid molecule which is complementary thereto,
3. (c) nucleic acid molecules which encode the same polypeptide as a nucleic acid molecule of (a) and/or (b), and
4. (d) nucleic acid molecules which encode a polypeptide which is at least 40%, preferably at least 60%, more preferably at least 80%, and most preferably at least 90% identical to a polypeptide encoded by a nucleic acid molecule of (a) over its entire length.

[0021] The nucleic acid molecules may be e.g. DNA molecules or RNA molecules.

[0022] As used herein, the terms '**regulators**' or '**effectors**' or '**modulators**' of Rspordin polypeptides or nucleic acids are used interchangeably herein and any of the above may be used to refer to antibodies, peptides, low molecular weight organic or inorganic molecules and other sources of potentially biologically active materials capable of modulating Rspordin polypeptides, e.g. Rspo2 and/or Rspo3 signal transduction or capable of modulating Rspordin polypeptide activity or capable of modulating Rspordin expression to promote (agonists) or inhibit (antagonists) angiogenesis and/or vasculogenesis. Said regulators, effectors or modulators can be naturally occurring or synthetically produced.

[0023] As used herein, the term '**compound capable of binding to Rspordin**' refers to a naturally occurring or synthetically produced regulator, effector or modulator of Rspordin which interacts with an Rspordin polypeptide. Examples of such compounds are (i) a natural partner, e.g. receptor of an Rspordin; (ii) a naturally occurring molecule which is part of the signalling complex; and/or a naturally occurring signalling molecule produced by other cell types; (iii) naturally occurring or synthetically produced antibody. The term 'compound' is used herein in the context of a 'test compound' or a 'drug candidate compound'.

[0024] As used herein the term '**agonist of Rspordin**' refers to regulators or effectors or modulators of Rspordin that activate the intracellular response of Rspordin and thus promote angiogenesis and/or vasculogenesis.

[0025] As used herein, the term '**antagonist of Rspordin**' refers to regulators or effectors or modulators of Rspordin polypeptides or Rspordin nucleic acids that inhibit, decrease or prevent the intracellular response of Rspordin polypeptides or Rspordin nucleic acids and thus inhibit, decrease or prevent angiogenesis and/or vasculogenesis.

[0026] Examples of suitable antagonists are mutated forms of Rspordin, having a dominant negative effect, Rspordin-binding polypeptides, e.g. anti-Rspordin antibodies including recombinant antibodies or antibody fragments containing at least one Rspordin binding site. Further examples of Rspordin antagonists are nucleic acids capable of inhibiting Rspordin translation, transcription, expression and/or activity, e.g. aptamers, antisense molecules, ribozymes or nucleic acid molecules capable of RNA interference such as siRNA molecules including nucleic acid analogs such as peptidic nucleic acids or morpholino nucleic acids. Such nucleic acids may bind to or otherwise interfere with Rspordin nucleic acids.

[0027] As used herein, the term '**antibody**' or '**antibodies**' includes but is not limited to recombinant polyclonal, monoclonal, chimeric, humanized, or single chain antibodies or fragments thereof including Fab fragments, single chain fragments, and fragments produced by an Fab expression library. Neutralizing antibodies i.e., those which compete for the VEGF binding site of an Rspordin are especially preferred for diagnostics and therapeutics.

[0028] As used herein, the term '**vasculogenesis**' refers to the formation and spreading of blood vessels.

[0029] As used herein, the term '**angiogenesis**' relates to a process which involves the vascularisation of a tissue, in particular, the proliferation, migration and infiltration of vascular endothelial cells and the growth and the development of new capillary blood vessels.

[0030] As used herein, the term '**treating**' or '**treatment**' refers to an intervention performed with the intention of preventing the development or altering the pathology of, and thereby alleviating a disorder, disease or condition, including one or more symptoms of such disorder or condition. Accordingly, 'treating' refers to both therapeutic treatment and prophylactic or preventative measures. Those in need of treating include those already with the disorder as well as those in which the disorder is to be prevented. The related term 'treatment', as used herein, refers to the act of treating a disorder, symptom, disease or condition, as the term 'treating' is defined above.

[0031] As used herein the term "**conditions where treatment involves inhibiting angiogenesis and/or vasculogenesis**" specifically includes (without limitation) conditions such as tumor growth, e.g. solid tumor growth and metastatic activity, atherosclerosis, stenosis, restenosis, retinopathy, macular degeneration, psoriasis and rheumatoid arthritis.

[0032] As used herein, the term '**Conditions where treatment involves promoting angiogenesis- &/or vasculogenesis**' specifically includes (without limitation) conditions such as wound healing, tissue and organ regeneration or development, vasculodegenerative processes (e.g. critical limb- or brain ischemia, ischemic heart disease), embryonic development, and reproductive processes, e.g. female reproduction processes, such as follicle development in the corpus luteum during ovulation and placental growth during pregnancy.

[0033] As used herein, the term "**tumor**" refers to a malignant new growth that arises from epithelium, found in skin or, more commonly, the lining of body organs, for example, breast, prostate, lung, kidney, pancreas, stomach or bowel. A tumor may also infiltrate into adjacent tissue and spread (metastasise) to distant organs, for example to bone, liver, lung or the brain. As used herein the term tumor includes both primary and metastatic tumor cell types, such as but not limited to, melanoma, lymphoma, leukaemia, fibrosarcoma, rhabdomyosarcoma, and mastocytoma and types of tissue carcinoma, such as but not limited to, colorectal cancer, prostate cancer, small cell lung cancer and non-small cell lung cancer, breast cancer, pancreatic cancer, bladder cancer, renal cancer, gastric cancer, glioblastoma, primary liver cancer and ovarian cancers.

5.2 Detailed Description of the Invention

[0034] The present invention is defined by the attached set of claims.

[0035] Angiogenesis is required for a number of physiological processes ranging from wound healing, tissue and organ regeneration, embryonic development and reproductive processes such as follicle development in the corpus luteum during ovulation and placental formation during pregnancy. Abnormal proliferation of blood vessels is an important component of a variety of diseases such as rheumatoid arthritis, retinopathies, and psoriasis, these diseases (and related conditions) are referred to herein as "conditions where treatment involves inhibiting angiogenesis and/or vasculogenesis". Angiogenesis is also an important factor in the growth and metastatic activity of solid tumors that rely on vascularization. Therefore, inhibitors of angiogenesis may be used therapeutically for the treatment of diseases resulting from or accompanied by abnormal growth of blood vessels and for treatments of malignancies involving growth and spread of solid tumors.

[0036] The present invention relates to the use of Rspordin polypeptides or Rspordin nucleic acids.

[0037] A first aspect of the present invention relates to the use of an Rspordin polypeptide or an Rspordin nucleic acid for the manufacture of an angiogenesis and/or vasculogenesis-promoting medicament.

[0038] A further aspect of the invention relates to the use of an Rspordin antagonist for the manufacture of an angiogenesis and/or vasculogenesis-inhibiting medicament.

[0039] Herein disclosed are methods and reagents for the diagnosis or monitoring of angiogenesis- and/or vasculogenesis-associated processes, conditions or disorders, comprising determining the amount, activity and/or expression of an Rspordin polypeptide or an Rspordin nucleic acid in a sample. Also in the method disclosed herein, the amount, activity and/or expression of an Rspordin polypeptide or an Rspordin nucleic acid in said sample is compared to the amount, activity and/or expression of said Rspordin polypeptide or Rspordin nucleic acid in a control sample. Further disclosed are recombinant cells and transgenic non-human animals exhibiting modified, e.g. increased or decreased Rspordin polypeptide expression.

[0040] The use of Rspordin polypeptides and Rspordin nucleic acids is disclosed to evaluate and screen test compounds for their ability to modulate, e.g. stimulate or inhibit angiogenesis- and/or vasculogenesis-associated processes, conditions or disorders. Such regulators of Rspordin may be used therapeutically. For example, agonists of Rspordin, e.g. Rspo2 and/or Rspo3 may be used in processes such as wound healing; in contrast, antagonists of Rspo3 may be used in the treatment of tumors that rely on vascularization for growth.

[0041] The invention is based, in part, on results from *in situ*-hybridization indicating that Rspo3 is expressed in the embryonic vasculature. The invention is also based on the discovery that expression of Rspo3 promotes endothelial cell differentiation, proliferation and morphogenesis, while inhibition by antisense molecules in *Xenopus* embryos or targeted mutagenesis in knock out mice interferes with angiogenesis. The invention is also based on the

discovery that Rspo3 is a positive regulator, which is both necessary and sufficient for expression of the key angiogenic factor VEGF.

[0042] Accordingly, inhibition of Rspordin molecules may be useful for treatment of diseases resulting from abnormal proliferation of blood vessels mediated by Rspordin, e.g. Rspo2 and/or Rspo3, and/or VEGF, where treatment involves inhibiting angiogenesis and/or vasculogenesis. The present invention relates to Rspordin polypeptides or Rspordin nucleic acids.

[0043] According to the present invention, an Rspordin polypeptide or a Rspordin nucleic acid may be used for promoting angiogenesis and/or vasculogenesis, particularly for the manufacture of an angiogenesis- and/or vasculogenesis-promoting medicament.

[0044] This embodiment encompasses the prevention or treatment of a condition where treatment involves promoting angiogenesis and/or vasculogenesis.

[0045] Rspordin polypeptides or Rspordin nucleic acids may be used in human or veterinary medicine, either alone or in combination with a further medicament, e.g. a further angiogenesis- and/or vasculogenesis-promoting medicament such as a FGF, VEGF, PDGF, TNF or L-lysine.

[0046] A method for promoting angiogenesis in a cell or an organism comprising increasing the level, activity and/or expression of an Rspordin polypeptide is disclosed. This method may be carried out *in vitro* or *in vivo*, e.g. for therapeutic applications.

[0047] Further, disclosed is a method for promoting angiogenesis comprising administering to a subject in need thereof a therapeutically effective dose of an Rspordin polypeptide or a Rspordin nucleic acid, wherein the subject is preferably human.

[0048] A different embodiment of the present invention refers to the use of an Rspordin antagonist for the manufacture of an angiogenesis- and/or vasculogenesis-inhibiting medicament. The Rspordin antagonist is preferably an Rspordin2 and/or Rspordin3 antagonist.

[0049] This embodiment of the present invention encompasses the prevention or treatment of a condition where treatment involves inhibiting angiogenesis and/or vasculogenesis.

[0050] In a preferred embodiment, the Rspordin antagonist may be used in human or veterinary medicine, alone or in combination with a further medicament. For example, the treatment of tumors may comprise the combined use of an Rspordin antagonist and an anti-tumor agent, e.g. a chemotherapeutic agent or an anti-tumor antibody, e.g. Bevacizumab, Endostatin, Thalidomide, Combrestatin A4, an anti VEGF antibody, SU 5416 or SU 6668.

[0051] Preferably, the nucleic acid molecules are recombinant DNA molecules that direct the

recombinant expression of Rspordin polypeptides in appropriate host cells. Alternatively, nucleotide sequences which hybridize to portions of an Rspordin-coding sequence may also be used in nucleic acid amplification and/or hybridization assays, e.g. PCR, Southern and Northern blot analyses, etc.

[0052] Due to the inherent degeneracy of the genetic code, nucleic acid molecules which encode substantially the same or a functionally equivalent polypeptide, may be used in the practice of the invention for the cloning and expression of an Rspordin, e.g. Rspo2 or 3 protein. Such DNA sequences include those which are capable of hybridizing to the *Xenopus*, and murine and/or human Rspordin sequences under stringent conditions. Preferably, hybridization under stringent conditions means that after washing for 1 h with 1 x SSC buffer and 0.1 % SDS, preferably at 55°C, more preferably at 62°C, and most preferably at 68°C, particularly for 1 h in 0.2 x SSC buffer and 0.1 SDS at 50°C, preferably at 55°C, more preferably at 62°C and most preferably at 68°C, a positive hybridization signal is observed.

[0053] The nucleic acid molecules of the invention may be engineered in order to alter the Rspordin-coding sequence for a variety of purposes including but not limited to alterations which modify processing and/or expression of the gene product. For example, mutations may be introduced using techniques which are well known in the art, e.g. site-directed mutagenesis, to insert new restriction sites, to alter glycosylation patterns, phosphorylation, etc. For example, in certain expression systems such as yeast, host cells may over glycosylate the gene product. When using such expression systems it may be preferable to alter the Rspo2 or 3-coding sequence to eliminate any N-linked glycosylation site.

[0054] In another aspect, the Rspordin nucleic acid sequence may be ligated to a heterologous sequence to encode a fusion protein. For example, for screening of peptide libraries it may be useful to encode a chimeric Rspordin protein expressing a heterologous epitope that is recognized by a commercially available antibody. A fusion protein may also be engineered to contain a cleavage site located between the Rspordin sequence and the heterologous protein sequence, so that the Rspordin portion can be cleaved away from the heterologous moiety.

[0055] In an alternative aspect, the coding nucleic acid sequence can be synthesized in whole or in part, using chemical methods well known in the art. See, for example, Caruthers, et al., 1980, Nuc. Acids Res. Symp. Ser. 7: 215-233; Crea and Horn, 1980, Nuc. Acids Res. 9(10): 2331; Matteucci and Caruthers, 1980, Tetrahedron Letters 21: 719; and Chow and Kempe, 1981, Nuc. Acids Res. 9(12): 2807-2817. Alternatively, the protein itself can be produced using chemical methods to synthesize the Rspordin amino acid sequence in whole or in part. For example, peptides can be synthesized by solid phase techniques, cleaved from the resin, and purified by preparative high performance liquid chromatography (e.g., see Creighton, 1983, Proteins Structures And Molecular Principles, W. H. Freeman and Co., N.Y. pp. 50-60). The composition of the synthetic peptides may be confirmed by amino acid analysis or sequencing (e.g., the Edman degradation procedure; see Creighton, 1983, Proteins, Structures and Molecular Principles, W. H. Freeman and Co., N.Y., pp. 34-49).

[0056] In order to express a biologically active Rspordin polypeptide, the nucleotide sequence coding for said polypeptide is inserted into an appropriate expression vector, i.e., a vector which contains the necessary elements for the transcription and translation of the inserted coding sequence. The Rspo gene products as well as host cells or cell lines transfected or transformed with recombinant expression vectors can be used for a variety of purposes. These include but are not limited to generating antibodies (i.e., monoclonal or polyclonal) that bind to Rspordin, including those that "neutralize" the activity of Rspordin.

[0057] Methods which are well known to those skilled in the art can be used to construct expression vectors containing the Rspordin-coding sequence and appropriate transcriptional/translational control signals. These methods include *in vitro* recombinant DNA techniques, synthetic techniques and *in vivo* recombination/genetic recombination. See, for example, the techniques described in Maniatis et al., 1989, Molecular Cloning A Laboratory Manual, Cold Spring Harbor Laboratory, N.Y. and Ausubel et al., 1989, Current Protocols in Molecular Biology, Greene Publishing Associates and Wiley Interscience, N.Y.

[0058] A variety of host-expression vector systems may be utilized to express the Rspordin-coding sequence. These include but are not limited to microorganisms such as bacteria transformed with recombinant bacteriophage DNA, plasmid DNA or cosmid DNA expression vectors containing the Rspordin-coding sequence; yeast cells transformed with recombinant yeast expression vectors containing the Rspordin-coding sequence; insect cell systems infected with recombinant virus expression vectors (e.g., baculovirus) containing the Rspo2 or 3-coding sequence; plant cell systems infected with recombinant virus expression vectors (e.g., cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or transformed with recombinant plasmid expression vectors (e.g., Ti plasmid) containing the Rspordin-coding sequence; or animal cell systems infected with recombinant virus expression vectors (e.g., adenovirus, vaccinia virus) including cell lines engineered to contain multiple copies of the Rspordin DNA either stably amplified (CHO/dhfr-) or unstably amplified in double-minute chromosomes (e.g., murine cell lines).

[0059] In a further aspect, Rspordin polypeptides, e.g. Rspo2 and/or Rspo3, Rspordin nucleic acids that express an Rspordin may be used to screen for regulators or effectors or modulators of Rspordin that act as agonists or antagonists of angiogenesis or vasculogenesis. For example, antibodies capable of neutralizing the activity of Rspordin, e.g. Rspo3 in an endothelial proliferation assay, a chicken CAM assay and/or a Xenopus VMZ differentiation assay, may be used to inhibit Rspordin function. Additionally, anti-Rspo3 antibodies which mimic VEGF activity may be selected for pro-angiogenic applications, e.g. in wound healing. Alternatively, screening of peptide libraries or organic compounds with recombinantly expressed soluble Rspordin polypeptides or cell lines or transgenic non-human animals expressing an Rspordin polypeptide may be useful for identification of therapeutic molecules that function by modulating, e.g. inhibiting the biological activity of Rspordin and thus are suitable as angiogenesis and/or vasculogenesis regulators or effectors or modulators of Rspordin, e.g. antagonists of Rspordin.

[0060] In a further aspect, engineered cell lines and/or transgenic non-human animals which exhibit modified Rspordin expression, e.g. an increased or decreased expression of an Rspordin compared to wild-type cell lines or animals, may be utilized to screen and identify antagonists as well as agonists. Synthetic compounds, natural products, and other sources of potentially biologically active materials can be screened in a number of ways to identify regulators or effectors or modulators of Rspordin. The ability of a test compound to inhibit the activity of an Rspordin polypeptide may be measured using an endothelial proliferation assay, a chicken CAM assay and/or a Xenopus VMZ differentiation assay, such as those described in the Examples.

[0061] Identification of molecules that are able to bind to an Rspordin polypeptide may be accomplished by screening a compound, e.g. a peptide library with a recombinant soluble Rspordin polypeptide. To identify and isolate a compound that interacts and forms a complex with Rspordin, it is preferred to label or "tag" the Rspordin polypeptide. The Rspordin polypeptide may be conjugated to labelling groups, e.g. enzymes such as alkaline phosphatase or horseradish peroxidase or to other reagents such as fluorescent labels which may include fluorescein isothiocyanate (FITC), phycoerythrin (PE) or rhodamine. Conjugation of any given label to Rspordin may be performed using techniques that are routine in the art. polypeptide containing an epitope for which a commercially available antibody exists. The epitope-specific antibody may be tagged using methods well known in the art including labeling with enzymes, fluorescent dyes or colored or magnetic beads.

[0062] The "tagged" Rspordin polypeptide conjugate may be incubated with a library of immobilized compounds under suitable conditions, e.g. for 30 minutes to one hour at 22°C to allow complex formation between the Rspordin polypeptide and an individual compound within the library. The library is then washed to remove any unbound Rspordin polypeptide. If Rspordin has been conjugated to alkaline phosphatase or horseradish peroxidase, the whole library may be poured into a petri dish containing a substrates for either alkaline phosphatase or peroxidase, for example, 5-bromo-4-chloro-3-indoyl phosphate (BCIP) or 3,3',4,4"-diaminobenzidine (DAB), respectively. After incubating for several minutes, the compound/solid phase-Rspordin complex changes color, and can be easily identified and isolated physically under a dissecting microscope with a micromanipulator. If a fluorescent tagged Rspordin molecule has been used, complexes may be isolated by fluorescent activated sorting. If a chimeric Rspordin polypeptide expressing a heterologous epitope has been used, detection of the compound/Rspordin complex may be accomplished by using a labeled epitope-specific antibody. Once isolated, the identity of the compound attached to the solid phase support may be determined, e.g. by peptide sequencing.

[0063] Cell lines or non-human transgenic animals that express Rspordin, e.g. Rspordin3, may be used to screen for regulators or effectors or modulators of Rspordin in a number of ways.

[0064] The ability of a regulator or effector or modulator of Rspordin to interfere with Rspordin activity and/or Rspordin signal transduction may be measured using an endothelial

proliferation assay, a chicken CAM assay or a *Xenopus* VMZ differentiation assay. Other responses such as activation or suppression of catalytic activity, phosphorylation or dephosphorylation of other proteins, activation or modulation of second messenger production, changes in cellular ion levels, association, dissociation or translocation of signalling molecules, or transcription or translation of specific genes may also be monitored. These assays may be performed using conventional techniques developed for these purposes in the course of screening.

[0065] Ligand binding to its cellular receptor may, via signal transduction pathways, affect a variety of cellular processes. Cellular processes under the control of the Rspordin signaling pathway may include, but are not limited to, normal cellular functions, proliferation, differentiation, maintenance of cell shape, and adhesion, in addition to abnormal or potentially deleterious processes such as unregulated cell proliferation, loss of contact inhibition, blocking of differentiation or cell death. The qualitative or quantitative observation and measurement of any of the described cellular processes by techniques known in the art may be advantageously used as a means of scoring for signal transduction in the course of screening.

[0066] Various embodiments are described below for screening, identification and evaluation of compounds that interact with Rspordin, which compounds may affect various cellular processes under the control of the Rspordin signalling pathway.

[0067] A method for identifying a regulator, effector or modulator of Rspordin is disclosed, comprising:

1. (a) contacting the putative regulator, effector or modulator of Rspordin with an Rspordin polypeptide, in pure or semi-pure form, or in a whole live or fixed cell or in a non-human transgenic animal,
2. (b) measuring the effect of the putative regulator, effector or modulator of Rspordin on the Rspordin polypeptide, the activity of the Rspordin, and/or on a phenotypic property of the cell or the organism mediated by the Rspordin,
3. (c) comparing the measured effect to that without the putative regulator, effector or modulator of Rspordin, thereby determining whether the putative regulator, effector or modulator of Rspordin stimulates or inhibits the intracellular response of the Rspordin.

[0068] Rspordins, e.g. Rspo3, useful in identifying a regulator, effector or modulator of Rspordin may be functionally equivalent to Rspordin. A functional equivalent to Rspordin may be prepared from a naturally occurring or recombinantly expressed Rspordin by proteolytic cleavage followed by conventional purification procedures known to those skilled in the art. Alternatively, the functional derivative may be produced by recombinant DNA technology by expressing parts of Rspordin which include the functional domain in suitable cells. Functional derivatives may also be chemically synthesized. Cells expressing Rspo3 may be used as a source of Rspordin, crude or purified, for testing in these assays. Alternatively, whole live or fixed cells may be used directly in those assays.

[0069] Rspordin signal transduction activity may be measured by an endothelial proliferation assay, a chicken CAM assay or a Xenopus VMZ differentiation assay and/or by monitoring the cellular processes controlled by the signal.

[0070] Also disclosed is a method whereby a molecule capable of binding to an Rspordin polypeptide may be identified comprising:

1. (a) immobilizing an Rspordin polypeptide or a functional equivalent thereof to a solid phase matrix;
2. (b) contacting the molecule with the solid phase matrix produced in step (a), for an interval sufficient to allow the molecule to bind;
3. (c) washing away any unbound material from the solid phase matrix;
4. (d) detecting the presence of the molecule bound to the solid phase.

[0071] The above method may further include the step of:

(e) eluting the bound molecule from the solid phase matrix, thereby isolating the molecule.

[0072] The above method may further include the step of:

(f) identifying the molecule eluted.

[0073] Various procedures known in the art may be used for the production of antibodies to epitopes of an Rspordin polypeptide, e.g. Rpo2 or Rspo3.

[0074] Monoclonal antibodies that bind to an Rspordin polypeptide may be radioactively labelled allowing one to follow their location and distribution in the body after injection. Radioactivity tagged antibodies may be used as a non-invasive diagnostic tool for imaging de novo vascularization associated with conditions where treatment involves inhibiting angiogenesis and/or vasculogenesis.

[0075] Immunotoxins may also be designed which target cytotoxic agents to specific sites in the body. For example, high affinity Rspordin-specific monoclonal antibodies may be covalently complexed to bacterial or plant toxins, such as diphtheria toxin, abrin or ricin. A general method of preparation of antibody/hybrid molecules may involve use of thiol-crosslinking reagents such as SPDP, which attack the primary amino groups on the antibody and by disulfide exchange, attach the toxin to the antibody. The hybrid antibodies may be used to specifically eliminate Rspordin expressing endothelial cells.

[0076] For the production of antibodies, various host animals may be immunized by injection with the Rspordin polypeptide including but not limited to rabbits, mice, rats, etc. Various adjuvants may be used to increase the immunological response, depending on the host species, including but not limited to Freund's (complete and incomplete), mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanin, dinitrophenol, and potentially useful human adjuvants such as BCG (bacille Calmette-Guerin) and Corynebacterium parvum.

[0077] Monoclonal antibodies to Rspordin may be prepared by using any technique which provides for the production of antibody molecules by continuous cell lines in culture. These include but are not limited to the hybridoma technique originally described by Kohler and Milstein, (Nature, 1975, 256: 495-497), the human B-cell hybridoma technique (Kosbor et al., 1983, Immunology Today, 4: 72; Cote et al., 1983, Proc. Natl. Acad. Sci., 80: 2026-2030) and the EBV-hybridoma technique (Cole et al., 1985, Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc., pp. 77-96). In addition, techniques developed for the production of "chimeric antibodies" (Morrison et al., 1984, Proc. Natl. Acad. Sci., 81: 6851-6855; Neuberger et al., 1984, Nature, 312: 604-608; Takeda et al., 1985, Nature, 314: 452-454) by splicing the genes from a mouse antibody molecule of appropriate antigen specificity together with genes from a human antibody molecule of appropriate biological activity can be used. Alternatively, techniques described for the production of single chain antibodies (U.S. Pat. No. 4,946,778) can be adapted to produce Rspordin-specific single chain antibodies.

[0078] Antibody fragments which contain specific binding sites for Rspo3 may be generated by known techniques. For example, such fragments include but are not limited to: the F(ab')₂ fragments which can be produced by pepsin digestion of the antibody molecule and the Fab fragments which can be generated by reducing the disulfide bridges of the F(ab')₂ fragments. Alternatively, Fab expression libraries may be constructed (Huse et al., 1989, Science, 246: 1275-1281) to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity to Rspordin.

[0079] Antibodies to Rspordin polypeptides may antagonise the activity of Rspordin by preventing it from binding to its usual partner in the Wnt signalling cascade. Therefore, antibodies which bind specifically to Rspordin, in particular to Rspo2 or Rspo3, may be antagonists of Rspordin which may be used to inhibit angiogenesis and/or vasculogenesis.

[0080] In addition, mutated forms of Rspordin, having a dominant negative effect, may be expressed in targeted cell populations to inhibit the activity of endogenously expressed wild-type Rspo3.

[0081] Included in the scope of the invention are nucleic acid antagonists of Rspordin. Anti-sense RNA and DNA molecules act to directly block the translation of mRNA by binding to targeted mRNA and preventing protein translation. In regard to antisense DNA, oligodeoxyribonucleotides derived from the translation initiation site, e.g., between -10 and +10 regions of the Rspordin nucleotide sequence, are preferred.

[0082] Ribozymes are enzymatic RNA molecules capable of catalyzing the specific cleavage of RNA. The mechanism of ribozyme action involves sequence-specific hybridization of the ribozyme molecule to complementary target RNA, followed by a endonucleolytic cleavage. Within the scope of the invention are engineered hammerhead motif ribozyme molecules that specifically and efficiently catalyze endonucleolytic cleavage of Rspo3 RNA sequences.

[0083] Specific ribozyme cleavage sites within any potential RNA target are initially identified by scanning the target molecule for ribozyme cleavage sites which include the following sequences, GUA, GUU and GUC. Once identified, short RNA sequences of between 15 and 20 ribonucleotides corresponding to the region of the target gene containing the cleavage site may be evaluated for predicted structural features such as secondary structure that may render the oligonucleotide sequence unsuitable. The suitability of candidate targets may also be evaluated by testing their accessibility to hybridization with complementary oligonucleotides, using ribonuclease protection assays.

[0084] RNAi molecules are double-stranded RNA molecules or analogues thereof capable of mediating RNA interference of a target mRNA molecule, e.g. siRNA molecules which are short double-stranded RNA molecules with a length of preferably 19-25 nucleotides and optionally at least one 3'-overhang or precursors thereof or DNA molecules coding therefor. Anti-sense RNA and DNA molecules, ribozymes and RNAi molecules of the invention may be prepared by any method known in the art for the synthesis of RNA molecules. These include techniques for chemically synthesizing oligodeoxyribonucleotides well known in the art such as for example solid phase phosphoramidite chemical synthesis. Alternatively, RNA molecules may be generated by *in vitro* and *in vivo* transcription of DNA sequences encoding the antisense RNA molecule. Such DNA sequences may be incorporated into a wide variety of vectors which incorporate suitable RNA polymerase promoters such as the T7 or SP6 polymerase promoters. Alternatively, antisense cDNA constructs that synthesize antisense RNA constitutively or inducibly, depending on the promoter used, can be introduced stably into cell lines.

[0085] Various modifications to the DNA molecules may be introduced as a means of increasing intracellular stability and half-life. Possible modifications include but are not limited to the addition of flanking sequences of Morpholino derivatives as well as ribo- or deoxy-nucleotides to the 5' and/or 3' ends of the molecule or the use of phosphorothioate or 2' O-methyl rather than phosphodiesterase linkages within the oligodeoxyribonucleotide backbone.

[0086] Expression and functional activity of Rspo3 correlates with the development of the vasculature and endothelial cell proliferation, indicating that Rspo3 is involved in the vascularization process. Rspindins, such as Rspo2 or 3, induce VEGF, and VEGF has been shown to be a mitogenic growth factor known to act exclusively on endothelial cells (Ferrara, N. and Henzel, W. J., 1989, Biochem. Biophys. Res. Comm. 161: 851-858).

[0087] In an aspect, Rspindin polypeptides such as Rspo2 or 3, can be administered *in vivo* to modulate angiogenesis and/or vasculogenesis. For example, the administration of Rspo2 or 3

may be used to treat conditions where treatment involves promoting angiogenesis and/or vasculogenesis, whereas antagonists of Rspo2 or 3 may be used to treat conditions where treatment involves inhibiting angiogenesis and/or vasculogenesis.

[0088] Particularly, Rspordin agonists may be used to treat conditions wherein treatment involves promoting angiogenesis and/or vasculogenesis. More particularly, said conditions are selected from the group consisting of wound healing, tissue and organ regeneration or development, vasculodegenerative processes (e.g. critical limb- or brain ischemia, ischemic heart disease), embryonic development, and reproductive processes such as follicle development in the corpus luteum during ovulation and placental growth during pregnancy. Specifically, said condition is selected from wound healing, tissue and organ regeneration or development, vasculodegenerative processes (e.g. critical limb- or brain ischemia, ischemic heart disease).

[0089] In a particular aspect, the Rspordin agonist is an Rspo2 agonist or an Rspo3 agonist.

[0090] In a particular aspect, the Rspordin agonist is selected from an Rspordin polypeptide, an Rspordin nucleic acid or a small molecule. Particularly, an Rspordin polypeptide may be used to treat conditions wherein treatment involves promoting angiogenesis or vasculogenesis. In a most particular aspect, an Rspordin nucleic acid may be used to treat conditions wherein treatment involves promoting angiogenesis and/or vasculogenesis.

[0091] In a particular embodiment of the invention Rspordin antagonists may be used in the treatment of conditions where treatment involves inhibiting angiogenesis e.g. tumor growth and metastatic activity, atherosclerosis, stenosis, restenosis, retinopathy, macular degeneration, psoriasis and rheumatoid arthritis. In a particular embodiment said condition is solid tumor growth. In a further particular embodiment said condition is macular degeneration. In a further particular embodiment said condition is rheumatoid arthritis.

[0092] In a particular embodiment of the invention the Rspordin antagonist is an Rspo2 antagonist or an Rspo3 antagonist.

[0093] In a particular embodiment of the invention the Rspordin antagonist is selected from an Rspordin antibody or a nucleic acid capable of inhibiting Rspordin translation, transcription, expression and/or activity. In a most particular embodiment of the invention an Rspordin antibody may be used to treat conditions wherein treatment involves inhibiting angiogenesis or vasculogenesis. In a most particular embodiment of the invention a nucleic acid capable of inhibiting Rspordin translation, transcription, expression and/or activity may be used to treat conditions wherein treatment involves promoting angiogenesis or vasculogenesis. In a most particular embodiment of the invention an siRNA or antisense nucleic acid against Rspordin may be used to treat conditions where treatment involves promoting angiogenesis or vasculogenesis.

[0094] Pharmaceutically active regulators or effectors or modulators of Rspordin can be

administered to a patient either by itself, or in pharmaceutical compositions where it is mixed with suitable carriers or excipient(s).

[0095] Depending on the specific conditions being treated, these agents may be formulated and administered systemically or locally. Techniques for formulation and administration may be found in "Remington's Pharmaceutical Sciences," Mack Publishing Co., Easton, Pa., latest edition. Suitable routes may, for example, include oral, rectal, transmucosal, or intestinal administration; parenteral delivery, including intramuscular, subcutaneous, intramedullary injections, as well as intrathecal, direct intraventricular, intravenous, intraperitoneal, intranasal, or intraocular injections, or, in the case of solid tumors, directly injected into a solid tumor. For injection, the agents of the invention may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hanks's solution, Ringer's solution, or physiological saline buffer. For transmucosal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.

[0096] The regulators or effectors or modulators of Rspordin can be formulated readily using pharmaceutically acceptable carriers well known in the art into dosages suitable for oral administration. Such carriers enable the regulators or effectors or modulators of Rspordin of the invention to be formulated as tablets, pills, capsules, liquids, gels, syrups, slurries, suspensions and the like, for oral ingestion by a patient to be treated.

[0097] Pharmaceutical compositions suitable for use in the present invention include compositions wherein the regulators or effectors or modulators of Rspordin are contained in an effective amount to achieve its intended purpose. Determination of the effective amounts is well within the capability of those skilled in the art, especially in light of the detailed disclosure provided herein.

[0098] In addition to the regulators or effectors or modulators of Rspordin these pharmaceutical compositions may contain suitable pharmaceutically acceptable carriers comprising excipients and auxiliaries which facilitate processing of the regulators or effectors or modulators of Rspordin into preparations which can be used pharmaceutically. The preparations formulated for oral administration may be in the form of tablets, dragees, capsules, or solutions.

[0099] The pharmaceutical compositions disclosed above may be manufactured in a manner that is itself known, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or lyophilizing processes.

[0100] Pharmaceutical formulations for parenteral administration include aqueous solutions of the regulators or effectors or modulators of Rspordin in water-soluble form. Additionally, suspensions of the regulators or effectors or modulators of Rspordin may be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes. Aqueous injection suspensions may contain substances which increase the

viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Optionally, the suspension may also contain suitable stabilizers or agents which increase the solubility of the regulators or effectors or modulators of Rspordin to allow for the preparation of highly concentrated solutions.

[0101] Pharmaceutical preparations for oral use can be obtained by combining the regulators or effectors or modulators of Rspordin with solid excipient, optionally grinding a resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores. Suitable excipients are, in particular, fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol; cellulose preparations such as, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl-cellulose, sodium carboxymethylcellulose, and/or polyvinylpyrrolidone (PVP). If desired, disintegrating agents may be added, such as the cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate.

[0102] Dragee cores are provided with suitable coatings. For this purpose, concentrated sugar solutions may be used, which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dyestuffs or pigments may be added to the tablets or dragee coatings for identification or to characterize different combinations of regulators or effectors or modulators of Rspordin doses.

[0103] Pharmaceutical preparations which can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol. The push-fit capsules can contain the regulators or effectors or modulators of Rspordin in admixture with filler such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers. In soft capsules, the regulators or effectors or modulators of Rspordin may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols. In addition, stabilizers may be added.

[0104] Compositions comprising a regulators or effectors or modulators of Rspordin formulated in a compatible pharmaceutical carrier may be prepared, placed in an appropriate container, and labelled for treatment of an indicated condition. Suitable conditions indicated on the label may include treatment of a tumor, such as a glioma or glioblastoma; and, other conditions where treatment involves inhibiting angiogenesis and/or vasculogenesis.

[0105] Compositions comprising a regulators or effectors or modulators of Rspordin of the invention formulated in a compatible pharmaceutical carrier may be prepared, placed in an appropriate container, and labelled for treatment of an indicated condition. Suitable conditions indicated on the label may include treatment of a conditions where treatment involves promoting angiogenesis and/or vasculogenesis, in particular wound healing.

[0106] The pharmaceutical compositions also may comprise suitable solid or gel phase carriers or excipients. Examples of such carriers or excipients include but are not limited to

calcium carbonate, calcium phosphate, various sugars, starches, cellulose derivatives, gelatin, and polymers such as polyethylene glycols.

[0107] Many of the regulators or effectors or modulators of Rspordin may be provided as salts with pharmaceutically compatible counterions. Pharmaceutically compatible salts may be formed with many acids, including but not limited to hydrochloric, sulfuric, acetic, lactic, tartaric, malic, succinic, etc. Salts tend to be more soluble in aqueous or other protonic solvents that are the corresponding free base forms.

[0108] For any regulator or effector or modulator of Rspordin used in the method disclosed above, the therapeutically effective dose can be estimated initially from cell culture assays. For example, a dose can be formulated in animal models to achieve a circulating concentration range that includes the IC₅₀ as determined in cell culture (i.e., the concentration of the test compound which achieves a half-maximal inhibition of the PTP activity). Such information can be used to more accurately determine useful doses in humans.

[0109] A therapeutically effective dose refers to that amount of the regulator or effector or modulator of Rspordin that results in amelioration of symptoms or a prolongation of survival in a patient. Toxicity and therapeutic efficacy of such regulators or effectors or modulators of Rspordin can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the LD₅₀ (the dose lethal to 50% of the population) and the ED₅₀ (the dose therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LD₅₀/ED₅₀. Regulators or effectors or modulators of Rspordin which exhibit large therapeutic indices are preferred. The data obtained from these cell culture assays and animal studies can be used in formulating a range of dosage for use in human. The dosage of such regulators or effectors or modulators of Rspordin lies preferably within a range of circulating concentrations that include the ED₅₀ with little or no toxicity. The dosage may vary within this range depending upon the dosage form employed and the route of administration utilized. The exact formulation, route of administration and dosage can be chosen by the individual physician in view of the patient's condition. (See e.g. Fingl et al., 1975, in "The Pharmacological Basis of Therapeutics", Ch. 1 p1).

[0110] Dosage amount and interval may be adjusted individually to provide plasma levels of the regulators or effectors or modulators of Rspordin which are sufficient to maintain the Rspo3 inhibitory or promoting effects. Usual patient dosages for systemic administration range from 1-2000 mg/day, commonly from 1-250 mg/day, and typically from 10-150 mg/day. Stated in terms of patient body weight, usual dosages range from 0.02-25 mg/kg/day, commonly from 0.02-3 mg/kg/day, typically from 0.2-1.5 mg/kg/day. Stated in terms of patient body surface areas, usual dosages range from 0.5-1200 mg/m² /day, commonly from 0.5-150 mg/m²/day, typically from 5-100 mg/m²/day.

[0111] Dosage amount and interval may be adjusted individually to provide plasma levels of the regulator or effector or modulator of Rspordin which are sufficient to maintain the

Rspondin inhibitory or promoting effects. Usual average plasma levels should be maintained within 50-5000 µg/ml, commonly 50-1000 µg/ml, and typically 100-500 µg/ml.

[0112] Alternately, one may administer the regulator or effector or modulator of Rspondin in a local rather than systemic manner, for example, via injection of the regulator or effector or modulator of Rspondin directly into a tumor, often in a depot or sustained release formulation.

[0113] Furthermore, one may administer the pharmaceutical composition in a targeted drug delivery system, for example, in a liposome coated with tumor-specific antibody. The liposomes will be targeted to and taken up selectively by the tumor.

[0114] In cases of local administration or selective uptake, the effective local concentration of the pharmaceutical composition may not be related to plasma concentration.

[0115] The Rspondin nucleic acids or compounds capable of binding to Rspondin, such as antibodies may be used for diagnostic purposes for detection of Rspondin expression in angiogenesis- and/or vasculogenesis-associated processes, conditions or disorders.

[0116] Reagents suitable for detecting Rspondins, such as Rspondin nucleic acids or compounds capable of binding to Rspondin may have a number of uses for the diagnosis of processes, conditions or diseases resulting from, associated with and/or accompanied by, aberrant expression of Rspondin. The diagnostic procedures are preferably carried out on samples obtained from a subject, e.g. a human patient, e.g. samples from body fluids such as whole blood, plasma, serum or urine, or tissue samples such as biopsy or autopsy samples. For example, the Rspondin sequence may be used in amplification, e.g. hybridization assays to diagnose abnormalities of Rspondin expression; e.g., Southern or Northern analysis, including *in situ* hybridization assays.

[0117] The Rspondin cDNA may be used as a probe to detect the expression of the corresponding mRNA. In a specific example described herein, the expression of Rspo3 mRNA in mouse embryos was analyzed (FIG. 4). Rspo3 mRNA was found to be enriched in embryonic vessels, indicating a role for Rspo3 in endothelial cell proliferation.

[0118] Further, the present invention is explained in more detail by the following Example.

6 EXAMPLE

6.1 MATERIALS AND METHODS

Rspo Coding Sequences

[0119] The nucleotide-coding sequence and deduced amino acid sequence of the murine and Xenopus Rsp3 genes as deposited in Genbank used here are

| | |
|---------------|------------------------------------|
| X. laevis | Rsp3 [gi:54145367] (SEQ ID NO: 1) |
| X. tropicalis | Rsp3 [gi:114149217] (SEQ ID NO: 2) |
| M. musculus | Rsp3 [NM_028351] (SEQ ID NO: 3) |

Mouse and Xenopus Embryos

[0120] Balb/c mice were mated overnight and the morning of vaginal plug detection was defined as 1/2 day of gestation. For routine histological analysis, tissues were fixed in 4% paraformaldehyde overnight and embedded in paraffin wax for sectioning. Generally, 4 μ m sections were cut and stained with Hemalum and Eosine. For wholemount *in situ* hybridization, the embryos were fixed and processed as described (del Barco et al., 2003, Genes Dev. 17, 2239-2244). Xenopus embryos were obtained by *in vitro* fertilization and cultivated as described (Gawantka et al 1995 EMBO J. 14, 6268-79). Xenopus embryos were fixed and processed for whole mount *in situ* hybridization as described (Bradley et al., 1996 Development 122, 2739-2750). Ventral marginal zone were excised and cultivated as described (Gawantka et al 1995 EMBO J. 14, 6268-79). Full length Rsp3 cDNAs were used to generate antisense riboprobes.

[0121] Rsp3 knock out mice were obtained by targeted mutagenesis of murine Rsp3 (gi:94388197) in mouse embryonic stem cells following standard procedures, using a targeting vector shown in FIG. 5. Transgenic mice were generated on a C57BL/6 background via standard diploid injection. Homozygous mutant embryos were generated by heterozygote intercrosses. C57BL/6 heterozygotes were then backcrossed to CD1 females for at least 6 generations. No serious phenotypic differences were detected between homozygous embryos in C57BL/6 and CD1 background. Mouse tail tips or portions of yolk sacs or embryos were used for genotyping by PCR. Genotyping was routinely performed by PCR analysis using 3 primers, 5'-ATGCTTGAGGCTTGACC-3' (SEQ ID NO: 4), 5'-TGCACCGACTCCAGTACTGG-3' (SEQ ID NO: 5) and 5'-TACATTCTGGTTCTCATCTGG-3' (SEQ ID NO: 6).

RT-PCR

[0122] RT-PCR assays were carried out as described (Gawantka et al 1995 EMBO J. 14,6268-79); additional primers were; XSCL (forward, actcacccctccagacaagaa (SEQ ID NO: 7); reverse, atttaatcaccgctgcccac (SEQ ID NO: 8)); α -globin (forward, tccctcagacccaaacctac (SEQ ID NO: 9); reverse, cccctaatttatgctggac (SEQ ID NO: 10)); Xmsr (forward, aacttcgctctcgctcctccatac (SEQ ID NO: 11); reverse, gccagcagatagcaaacaccac (SEQ ID NO: 12)), VEGF (forward,

aggcgagggagaccataaac (SEQ ID NO: 13); reverse, tctgctgcattcacactgac (SEQ ID NO: 14)).

Preparation of *Xenopus laevis* Rspo2-conditioned medium

[0123] Transfection of HEK293T cells with *Xenopus laevis* Rspo2 (gi:54145367) and harvest of conditioned medium were as described (Kazanskaya et al., 2004, Dev. Cell 7, 525-534).

Endothelial proliferation assay.

[0124] Human Umbilical Vein Endothelial Cells (HUVEC) (PromoCell) were cultured in Endothelial cell Growth Medium (Promocell) supplemented with 10% fetal bovine serum (FBS). For proliferation studies, cells were plated at 50% confluence in 96-well plate, next day they were supplemented with VEGF and *Xenopus laevis* Rspo2 proteins for 48 h, after which BrdU (10 µM) was added to each well for 4 h. BrdU analysis of cell proliferation was carried out using Cell Proliferation ELISA BrdU chemiluminescent from Roche Applied Science.

Chorioallantoic membrane (CAM) assay

[0125] For chicken chorioallantoic membrane (CAM) assay, chicken eggs were incubated at 37°C in a humidified chamber. On day 3 of development, a window was made in the outer shell and on 6 day of development a 20 µl of Rspo2 or control beads or filter disk (3MM Whatman-8 mm diameter) carrying recombinant VEGF (Sigma-Aldrich, 100 ng/filter) was placed onto the surface of the CAM. The beads (ANTI-FLAG M2-Agarose, Sigma) were incubated overnight with *Xenopus laevis* Rspo2-conditioned medium or control medium from untransfected HEK 293T cells and washed 3 times in PBS. After 5 days of incubation, the filter disks and the attached CAM were excised, washed with PBS and processed for histology using Hematoxylin-Eosine staining.

Antisense Morpholino oligonucleotide

[0126] Based on *Xenopus tropicalis* Rspo3 cDNA sequence (gi:114149217), an antisense morpholino oligonucleotide was designed (sequence: 5': atgcaattgcgactgcttctctgt (SEQ ID NO: 15)).

6.2 RESULTS

[0127] FIG.1 shows that an antisense morpholino oligonucleotide which is directed against

Xenopus tropicalis Rspo3, inhibited the development of forming blood vessels in *Xenopus* tadpoles. A marker for forming blood vessels is the gene msr, which was down-regulated. Inhibition of blood vessel development - in other words embryonic angiogenesis - is accompanied by expansion of blood cell development, since blood cell markers α -globin and SCL are expanded. The results suggest that Rspo3 is a developmental regulator that switches cell fate between blood and blood vessel development. The specificity of the morpholino-induced phenotype for inhibition of Rspo3 is demonstrated by the rescue experiment in FIG. 2. In this experiment, the related molecule Rspo2 was able to revert the expansion of blood marker α -globin.

[0128] The ability of Rspo2 to promote angiogenesis in *Xenopus* embryos is shown in an ventral marginal zone (VMZ) assay FIG. 3. Overexpression of Rspo2 mRNA inhibits blood cell markers and induces the endothelial marker msr, as well as the angiogenic factor VEGF. Conversely, the requirement of endogenous Rspo3 for embryonic angiogenesis is shown by the inhibition of msr and VEGF by an antisense morpholino oligonucleotide.

[0129] By way of the examples in FIGs. 1-3 it is demonstrated that inhibition of Rspo3 in a vertebrate inhibits VEGF, vasculogenesis and angiogenesis. Therefore, antagonists of Rspo3 will be useful to deliberately inhibit VEGF, vasculogenesis and angiogenesis where this is useful, e.g. in conditions where treatment involves inhibiting angiogenesis and / or vasculogenesis.

[0130] The ability of Rspindins to promote angiogenesis is not limited to *Xenopus* but also extends to mammals, e.g. to the mouse. Rspo3 is expressed in murine embryonic blood vessels (FIG. 4). Furthermore, Rspo3 mutant mice show defective angiogenesis. This is demonstrated by the early lethality of such mutant mice, which show internal bleedings, as is characteristic for a failure to form blood vessels (FIG. 6). The deficient angiogenesis is also evidenced by the reduced blood vessels in the yolk sac of mutant embryos (FIG. 7). Furthermore, the inactivation of Rspo3 is accompanied with downregulation of VEGF in mutant placentas (FIG. 8). By way of these examples it is again demonstrated that inhibition of Rspo3 in a mammal inhibits VEGF, vasculogenesis and angiogenesis.

[0131] The ability of Rspo2 to induce angiogenesis is demonstrated in two standard *in vitro* angiogenesis assays. In the chicken choriallantois membrane (CAM) assay, the ability of regulators or effectors or modulators of Rspindin to promote the growth of endothelial cells and blood vessels is measured. A strong induction of endothelial cell growth and of blood vessels was observed following implantation of beads soaked with VEGF or Rspo2 conditioned medium (FIG. 9). Furthermore, Rspo2 conditioned medium induced branching morphogenesis in endothelial cells (FIG. 10), a characteristic response to angiogenic factors. In addition Rspo2 induced proliferation of endothelial cells, similar to the angiogenic factor VEGF (FIG. 11).

[0132] The present invention is not to be limited in scope by the exemplified embodiments which are intended as illustrations of single aspects of the invention, and any clones, DNA or functionally equivalents to Rspindin are within the scope of the invention. Indeed, various

modifications of the invention in addition to those described herein will become apparent to those skilled in the art from the foregoing description and accompanying drawings. Such modifications are intended to fall within the scope of the appended claims.

SEQUENCE LISTING

[0133]

<110> Deutsches Krebsforschungszentrum

<120> Rspondins as Modulators of Angiogenesis and Vasculogenesis

<130> 38994P WO

<150> EP 06022070

<151> 2006-10-20

<160> 23

<170> PatentIn version 3.3

<210> 1

<211> 1432

<212> DNA

<213> Xenopus laevis

<220>

<221> gene

<222> (1)..(1432)

<223> Xenopus laevis Rspondin 2

<400> 1

| | | | | | | |
|-------------|-------------|------------|------------|-------------|-------------|-----|
| gggggtgatt | tcaaggccgt | ccaaatgcag | tttcaactct | tttcattcgc | cctgatcatc | 60 |
| ctgaactgtg | tggattacag | tcactgccaa | gcctcccgct | ggagacggag | caagagagcc | 120 |
| agctatggg | ccaacccgat | atgcaaaggt | tgcctgtcct | gctcaaaaga | taatgggtgc | 180 |
| ctccgctgcc | agccaaaact | gttttcttt | ctgcgaagag | aaggatgatg | gcagtatgga | 240 |
| gagtgtctgc | agtccctgccc | tccggatac | tatggagtca | gaggacctga | tatgaacagg | 300 |
| tgttccagat | gcagaattga | aaattgcgac | tcttgcattt | gtagagattt | ttgcataaaag | 360 |
| tgc当地atcg | gctttactc | cctcaagggg | caatgcattt | aagaatgccc | agaaggattt | 420 |
| gcaccactgg | atgataaccat | ggtgtgtgt | gatggctgcg | aagttagggcc | atggagtgaa | 480 |
| tggggcacat | gcagccgaaa | taacagaacg | tgcggtttca | aatggggcct | ggagaccaga | 540 |
| acgcgcacaaa | ttgtgaagaa | accagcaaaa | gacaccatcc | cctgcccac | tattgctgaa | 600 |
| tccagaagat | gtaagatggc | aataagacac | tgccctggag | gaaagagaac | tacaaagaag | 660 |
| aaggacaaga | ggaacaagaa | gaagaaaaag | aagttactgg | agagggccca | agagcagcac | 720 |
| agcgctgtcc | ttgctacaga | ccggcttagc | caatagagac | agatccttac | atttttcttt | 780 |

| | |
|---------------------------------------------------------------------|------|
| tttgctaagt gcacaacggc tgctacatgc tcttcacac gaatgaactg cggaaccgct | 840 |
| gccttaacag tattggttgc aaataacatg tgaaccgatt cacaagggtt tttgtgttat | 900 |
| ttatacattt ttaatttttt ttctctcaat ccggaaacttc caaaaaggag tgaacgctga | 960 |
| gttgaatcag tttttttttt taattttttt ttcttcgggtt | 1020 |
| tttattgttag tgcctgtgag gggcaactggc agaattcttt ttggaaaagg aactgttgt | 1080 |
| gaaattgcag aagctatcta caactactcg gacttgcgtt tatttctgtt aaaggaaaaaa | 1140 |
| aaaacagaat aaagaaaccc cttggggaa ccgacccaaat atcattttttt ttgcgtt | 1200 |
| ttacatactg tacatttcac gattgtacat gaaatatttgc ttttaggtgtt gtttgttccc | 1260 |
| agcgcctatt ttataaaac agttgtataa taaaactgtt taagctaata tactgtacta | 1320 |
| cagaggttaac tgctttttgtt ccctgttagc ctatggttt tttgtacata gtgctgagaa | 1380 |
| gtacacata ataaaacttat ttactgtgtt aaaaaaaaaa aaaaaaaaaa aa | 1432 |

<210> 2

<211> 786

<212> DNA

<213> Xenopus sp.

<220>

<221> gene

<222> (1)..(786)

<223> Xenopus tropicalis Rspordin 3

<400> 2

| | |
|-----------------------------------------------------------------------|-----|
| cattacaagg ttactatgca attgcgactg ctttctctgt gttttatcat attgaacttc | 60 |
| tttggaaataca ttgacagccca gcagatcccc agagggaggc gacatcgagg aatgcacatct | 120 |
| aatgtcagcc agggttgccca aggaggatgt gctacatgtt ctgattataa tggctgttta | 180 |
| acatgcaagc ctcagctgtt ttgcgtttt gtaagaaatg gaatgaagca aattggagtc | 240 |
| tgtcgccct cctgtccaaa tggatattttt gggatacgat caccagaaat aaataaatgt | 300 |
| acaaaatgca aagctgactg tgaaacatgt ttcaacaaaa atttctgcac aaagtgtaaa | 360 |
| agtggatttt acaaacacaa cggaaaagtgc tttagacacat gtcctgaagg gtttggaaac | 420 |
| aatcacaata tggagtgcac cagtgtggc cactgcgtag ttggggagtg gagcgcttgg | 480 |
| ggtccgtgca caaagagggg gaaaacctgt gacatcaagc gagggaaatga aacaagggtt | 540 |
| cgggaaattt tacaatacccc ttccacctagg ggcacacccct gtccgccaac atccgagaca | 600 |
| aaaaaaatgtg tagtaaagag aaagaaatgt caagacagtc aagacagaca aaggccaaga | 660 |
| ggcaacagag atgaaataaa aaagaataaa caaaggcgaa agaatggtga cgctcccaga | 720 |
| aaacaaagac agagaaagca agagagaaat cagcgagaag gaaagagagg ggagggcaaa | 780 |
| gtctaa | 786 |

<210> 3

<211> 946

<212> DNA

<213> Mus musculus

<220>
 <221> misc_feature
 <222> (1)..(946)
 <223> M. musculus Rspondin 3

<220>
 <221> gene
 <222> (1)..(946)
 <223> mus musculus Rspondin 3

<400> 3

| | |
|------------------------------------------------------------------------|-----|
| tcctgctcag aacgccagaa gcagctcggg tctctccagc gccccttgac catggctg | 60 |
| gtacccacgg cgtccgccttc cctgcgtcc cggggtcccgt gccacagccg cagccgctgc | 120 |
| agcctctgag ccccaaggggc cactgctcgc ctggattccg cccgcagccg ccgctgctgt | 180 |
| gcaaccgagg ctaacctgctg gccagccagg aggctctgc aaccttcgct cgccggcgatg | 240 |
| acagccaccc cagagcagcc ggctgtgttc ggacaatttg agaatgcaat tgggtttc | 300 |
| ccggtccacc cgtcccgctt cgcttgccat cacagcacgc ctgttgatc tcagtggaga | 360 |
| agtcccgctg ctctgggttt tctactcttc gtatagactc gcctaaccacc tacatacata | 420 |
| tttttttta aaaaaaaaca ttaaatataa ctaacagtga aaagaaaaag gagagaaaaaa | 480 |
| agggaaacat tacagggtaa ctatgcactt gcgactgatt tcttgggtttt ttatcattt | 540 |
| gaactttatg gaatacatttgcagccaaaa cgcctcccgaa ggaaggcgcc agcgaagaat | 600 |
| gcatcctaattgtca gtcagtcaag gctgccaagg aggctgtgca acgtgttcag attacaatgg | 660 |
| ctgtttgtca tgtaagccca gactgtttttt tggatggaa aggattggca tgaaggcagat | 720 |
| aggagtgtgt ctctcttcgt gtccaaatggg atattacggaa actcgatatc cagatataaaa | 780 |
| taaatgtaca aatgcaaaatggactgtga tacctgtttt aacaaaaatt tctgcacaaa | 840 |
| gtgtaaaatggatggact tacacccggaa agtgcctt gacagttgcc cagaagggtt | 900 |
| agaagccaaac aatcataactatggaaatgtgt cagtattgtat cagtaa | 946 |

<210> 4
 <211> 20
 <212> DNA
 <213> Artificial

<220>
 <223> Primer pair F1

<220>
 <221> primer_bind
 <222> (1)..(20)

<400> 4

| | |
|----------------------|----|
| atgcttgag gcttgtgacc | 20 |
|----------------------|----|

<210> 5
 <211> 20

<212> DNA

<213> Artificial

<220>

<223> Primer Pair R1

<220>

<221> primer_bind

<222> (1)..(20)

<400> 5 tgccaccgact ccagttactgg 20

<210> 6

<211> 22

<212> DNA

<213> Artificial

<220>

<223> Primer Trio 3rd

<220>

<221> primer_bind

<222> (1)..(22)

<400> 6

tacattctgg ttctcatct gg 22

<210> 7

<211> 20

<212> DNA

<213> Artificial

<220>

<223> XSCL forward

<220>

<221> primer_bind

<222> (1)..(20)

<400> 7

actcaccctc cagacaagaa 20

<210> 8

<211> 20

<212> DNA

<213> Artificial

<220>

<223> XSCL reverse

<220>

<221> primer_bind

<222> (1)..(20)

<400> 8

attaatcac cgctgcccac 20

<210> 9

<211> 20

<212> DNA

<213> Artificial

<220>

<223> A-globin forward

<220>

<221> primer_bind

<222> (1)..(20)

<400> 9

tccctcagac caaaacctac 20

<210> 10

<211> 21

<212> DNA

<213> Artificial

<220>

<223> A-globin reverse

<220>

<221> protein_bind

<222> (1)..(21)

<400> 10

ccccctaatt ttatgctgga c 21

<210> 11

<211> 24

<212> DNA

<213> Artificial

<220>

<223> Xmsr forward

<220>
<221> primer_bind
<222> (1)..(24)

<400> 11
aacttcgctc tcgctcctcc atac 24

<210> 12
<211> 22
<212> DNA
<213> Artificial

<220>
<223> Xmsr reverse

<220>
<221> primer_bind
<222> (1)..(22)

<400> 12
gccagcagat agcaaacacc ac 22

<210> 13
<211> 20
<212> DNA
<213> Artificial

<220>
<223> VEGF forward

<220>
<221> primer_bind
<222> (1)..(20)

<400> 13
aggcgaggga gaccataaac 20

<210> 14
<211> 20
<212> DNA
<213> Artificial

<220>
<223> VEGF reverse

<220>
<221> primer_bind
<222> (1)..(20)

<400> 14

tctgctgcat tcacactgac 20

<210> 15

<211> 25

<212> DNA

<213> Artificial

<220>

<223> Antisense morpholino

<220>

<221> misc_feature

<222> (1)..(25)

<400> 15

atgcaattgc gactgctttc tctgt 25

<210> 16

<211> 2995

<212> DNA

<213> Homo sapiens

<220>

<221> gene

<222> (1)..(2995)

<223> human Rspndin 1

<400> 16

| | |
|-------------------------------------------------------------------------|-----|
| gcgacccggcc agagtagggc atcccgctcgg gtgctgcgga gaacgagggc agctccgagc | 60 |
| cgcggccggag gaccgatgcg ccgggtgggg cgctggcccc gagggcgtga gccgtccgca | 120 |
| gattgagcaa cttggaaacg ggcgggcgga ggcgcaggcga gccggcgcc caggacagtc | 180 |
| ccgcaggcggg cgggtgagcg ggccgcgccc tcgccccctcc cgggcctgcgccc cccgtcgcgca | 240 |
| ctggcagcac gaagctgaga ttgtggtttc ctgggtgattc aggtgggagt gggccagaag | 300 |
| atcaccgctg gcaaggactg gtgtttgtca actgttaaggc ctcatggAAC agatctacca | 360 |
| gggattctca gaccttagtt tgagaaatgc tgcaattaaa ggcaaattcct atcaactctga | 420 |

| | |
|----------------------------------------------------------------------|-----|
| gtgatcgctt tgggtgcgag gcaatcaacc ataaagataa atgcaaataat ggaatttgc | 480 |
| taacagtact cagtattaag gttgggggggg gggatgtcc ctgctgacgt gacaaaaaga | 540 |
| tctctcatat gatattccga ggtatctttg aggaagtctc tctttgagga cctccctttg | 600 |
| agctgtatggaa gaactgggct ccccacaccc tctctgtccc cagctgagat tatgggtggat | 660 |
| ttgggctacg gcccaggcct gggcctcctg ctgctgaccc agccccagag gtgttagcaa | 720 |
| gagccgtgtg ctatccaccc tccccgagac cacccttcgg accagggggcc tggagctggc | 780 |
| gcgtgactat gcggcttggg ctgtgtgtgg tggccctggg tctgagctgg acgcacactca | 840 |
| ccatcagcag ccgggggatc aagggaaaaa ggcagaggcg gatcagtgcc gaggggagcc | 900 |

| | |
|---------------------------------------------------------------------|------|
| aggcctgtgc caaaggctgt gagctctgct ctgaagtcaa cggctgcctc aagtgctcac | 960 |
| ccaagctgtt ctcctgctg gagaggaacg acatccgcca ggtggcgctc tgcttgcgt | 1020 |
| cctgccccacc tggatacttc gacgcggca accccgacat gaacaagtgc atcaaatgca | 1080 |
| agatcgagca ctgtgaggcc tgcttcagcc ataacttctg caccaagtgt aaggagggct | 1140 |
| tgtacctgca caagggccgc tgctatccag cttgtcccga gggctctca gctgccaatg | 1200 |
| gcaccatgga gtgcagtagt cctgcgcaat gtgaaatgag cgagtggctc ccgtggggc | 1260 |
| cctgctccaa gaagcagcag ctctgtggtt tccggagggg ctccgaggag cggacacgca | 1320 |
| gggtgctaca tgccccctgtg ggggaccatg ctgcctgctc tgacaccaag gagacccgga | 1380 |
| ggtgcacagt gaggagagtg ccgtgtctg aggggcagaa gaggaggaag ggaggccagg | 1440 |
| gccggcggga gaatgcacaa aggaacctgg ccaggaagga gagcaaggag gcgggtgctg | 1500 |
| gctctcgaag acgcaagggg cagcaacagc agcagcagca agggacagtg gggccactca | 1560 |
| catctgcagg gcctgcctag ggacactgtc cagcctccag gcccattgcag aaagagttca | 1620 |
| gtgctactct gcgtgattca agcttcctg aacttggacg tcggggccaa agcatacaca | 1680 |
| cacactccaa tccatccatg catacataga cacaagacac acacgctcaa accctgtcc | 1740 |
| acatatacaa ccatacatac ttgcacatgt gtgttcatgt acacacgcag acacagacac | 1800 |
| cacacacaca catacacaca cacacacaca cacacctgag gccaccagaa gacacttcca | 1860 |
| tccctcgggc ccagcagtagc acacttggtt tccagagctc ccagtggaca tgcagagac | 1920 |
| aacacttccc agcatctgag accaaactgc agaggggagc cttctggaga agctgctgg | 1980 |
| atcgaccag ccactgtggc agatgggagc caagctttag gactgctggt gacctggaa | 2040 |
| gaaaccttct tcccatcctg ttcagcactc ccagctgtgt gactttatcg ttggagagta | 2100 |
| ttgttaccct tccaggatac atatcagggt taacctgact ttgaaaactg cttaaagggt | 2160 |
| tatccaat taaaacaaaa aaatcaacga cagcagtaga cacaggcacc acattcttt | 2220 |
| gcaggggtgtg agggtttggc gaggtatgcg taggagcaag aagggacagg gaattcaag | 2280 |
| agacccaaaa tagcctgctc agtagagggt catgcagaca aggaagaaaa cttagggct | 2340 |
| gctctgacgg tggtaaacag gctgtctata tccttgcgtac tcagagcatg gcccggcagc | 2400 |
| agtgttgtca cagggcagct gttaggaat gagaatctca ggtctcattc cagacctgg | 2460 |
| gagccaggt ctaaatttttta agattcctga tgattggcat gttacccaaa tttgagaagt | 2520 |
| gctgctgtaa ttcccccttaa aggacgggag aaaggccccccc ggcattttc cagcaggagg | 2580 |
| gattctggtc agctataaag gaggacttgc catctggag aggcagaatc tatatactga | 2640 |
| aggcttagtgc gcaactgcag gggaaaggag tgcgttaggt tccagtgtatg gttggggaca | 2700 |
| atccctgcccc aaggcagggc agtggatgga ataactcctt gtggcattctt gaaatgtgt | 2760 |
| ccaggctctg gacttaggtgc taggtttcca gggaggagcc aaacacgggc cttgctcttgc | 2820 |
| tggagcttag aggttggtgg ggaagaaaaat aggcatgcac caaggaatttgc tacaacaca | 2880 |
| tatataacta caaaaggatg gtgccaaggc caggtgacca ctggcatctt tgcttagctt | 2940 |
| tgaaagtgaa taaagcagaa taaaataaaa atactttctc tcagggaaaaaaa aaaaaa | 2995 |

<210> 17

<211> 263

<212> PRT

<213> Homo sapiens

<220>

<221> PEPTIDE

<222> (1)..(263)

<223> human Rspndin 1

<400> 17

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Met | Arg | Leu | Gly | Leu | Cys | Val | Val | Ala | Leu | Val | Leu | Ser | Trp | Thr | His |
| 1 | | | | 5 | | | | 10 | | | | | 15 | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Leu | Thr | Ile | Ser | Ser | Arg | Gly | Ile | Lys | Gly | Lys | Arg | Gln | Arg | Arg | Ile |
| | | | | 20 | | | 25 | | | 30 | | | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Ser | Ala | Glu | Gly | Ser | Gln | Ala | Cys | Ala | Lys | Gly | Cys | Glu | Leu | Cys | Ser |
| | | 35 | | | 40 | | | | 45 | | | | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Glu | Val | Asn | Gly | Cys | Leu | Lys | Cys | Ser | Pro | Lys | Leu | Phe | Ile | Leu | Leu |
| | | 50 | | | 55 | | | 60 | | | | | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Glu | Arg | Asn | Asp | Ile | Arg | Gln | Val | Gly | Val | Cys | Leu | Pro | Ser | Cys | Pro |
| 65 | | | | 70 | | | 75 | | | | 80 | | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Pro | Gly | Tyr | Phe | Asp | Ala | Arg | Asn | Pro | Asp | Met | Asn | Lys | Cys | Ile | Lys |
| | | 85 | | | 90 | | | | 95 | | | | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Cys | Lys | Ile | Glu | His | Cys | Glu | Ala | Cys | Phe | Ser | His | Asn | Phe | Cys | Thr |
| | | 100 | | | 105 | | | | 110 | | | | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Lys | Cys | Lys | Glu | Gly | Leu | Tyr | Leu | His | Lys | Gly | Arg | Cys | Tyr | Pro | Ala |
| | | 115 | | | 120 | | | 125 | | | | | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Cys | Pro | Glu | Gly | Ser | Ser | Ala | Ala | Asn | Gly | Thr | Met | Glu | Cys | Ser | Ser |
| | 130 | | | 135 | | | | 140 | | | | | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Pro | Ala | Gln | Cys | Glu | Met | Ser | Glu | Trp | Ser | Pro | Trp | Gly | Pro | Cys | Ser |
| 145 | | | | 150 | | | 155 | | | 160 | | | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Lys | Lys | Gln | Gln | Leu | Cys | Gly | Phe | Arg | Arg | Gly | Ser | Glu | Glu | Arg | Thr |
| | | | 165 | | | | 170 | | | 175 | | | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Arg | Arg | Val | Leu | His | Ala | Pro | Val | Gly | Asp | His | Ala | Ala | Cys | Ser | Asp |
| | | 180 | | | 185 | | | 190 | | | | | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Thr | Lys | Glu | Thr | Arg | Arg | Cys | Thr | Val | Arg | Arg | Val | Pro | Cys | Pro | Glu |
| | | 195 | | | 200 | | | 205 | | | | | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Gly | Gln | Lys | Arg | Arg | Lys | Gly | Gly | Gln | Gly | Arg | Arg | Glu | Asn | Ala | Asn |
| | | 210 | | | 215 | | | 220 | | | | | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Arg | Asn | Leu | Ala | Arg | Lys | Glu | Ser | Lys | Glu | Ala | Gly | Ala | Gly | Ser | Arg |
| 225 | | | | 230 | | | 235 | | | 240 | | | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|--|--|
| Arg | Arg | Lys | Gly | Gln | Gln | Gln | Gln | Gln | Gly | Thr | Val | Gly | Pro | | |
| | | 245 | | | 250 | | | 255 | | | | | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|--|--|--|--|--|--|--|--|--|
| Leu | Thr | Ser | Ala | Gly | Pro | Ala | | | | | | | | | |
| | | 260 | | | | | | | | | | | | | |

<210> 18

<211> 2842

<212> DNA

<213> Homo sapiens

<220>

<221> gene

<222> (1)..(2842)

<223> human Rspnsin 2

<400> 18

| | |
|-----------------------------------------------------------------------|-----|
| tggaattcca gagctgccag ggcgtcccaag cccgtctcggtt ccaaacttttcccccac | 60 |
| gtgcttaacca agccggctctc ttcccgagcc cgggatggag caccgcgcctt agggaggccg | 120 |
| cggcccccga gacgtgcgca cgggtcggtt cggagagatg ctgatcgccgc tgaactgacc | 180 |
| ggtgccggccc ggggggtgagt ggcgagtcctc cctctgagtc ctcccccagca ggcggccgg | 240 |
| cgcggctctt ttgggcgaac cctccagttt ctagactttt agaggcgtctt ctccccccgc | 300 |
| cgaccggccca gatgcagttt cgccttttctt ctttgcctt catcattctg aactgcattgg | 360 |
| attacagccca ctgccaaggc aaccatggaa gacgcagtaa gcgagatgtt tatgtatcaa | 420 |
| atccccattttt caagggttgtt ttgttttgtt caaaggacaa tgggtgttagc cgatgtcaac | 480 |
| agaagttgtt cttttccctt cgaagagaag ggatgcgcctt gatggagag tgcctgcattt | 540 |

| | |
|--------------------------------------------------------------------------------|------|
| cctggccatc cgggtactat ggacaccggag ccccaagatat gaacagatgtt gcaagatgc | 600 |
| gaatagaaaa ctgtgattct tgcttttagca aagacttttgc taccaagtgc aaagtaggtt | 660 |
| tttatttgca tagaggccgt tgctttgtatg aatgtccaga tggttttgc ccattagaag | 720 |
| aaaccatggaa atgtgtggaa ggatgtgaag ttgggtcattt gaggcaatgg ggaacttggta | 780 |
| gcagaaataa tcgcacatgtt ggatttaat ggggtctggaa aaccagaaca cggcaaattt | 840 |
| ttaaaaagcc agtggaaagac acaataccgt gtccaaaccat tgctgaatcc aggagatgc | 900 |
| agatgacaat gaggcattgtt ccaggaggaa agagaacacc aaaggcgaag gagaagagga | 960 |
| acaagaaaaaa gaaaaggaaatg ctgatagaaa gggcccagga gcaacacagc gtcttcctag | 1020 |
| ctacagacag agctaaccatgaa taaaacaaga gatccggtagt attttttaggg gtttttgtt | 1080 |
| ttgcaaatgtt gcacaaagctt actctccactt cctgcacactt ggtgtgcagc ctgtgtgt | 1140 |
| ctctggccatc tatctgttcc cagtaacatgt tgaaaggaa gcaccaccatg catggccctt | 1200 |
| gtgttatttt tgctttgtattt tgaatctggaa gactgtgaag gcaggagttt gtgcacagcc | 1260 |
| cgtgacttgg ctcagtgtgtt gctgagagaa tccgtccccg gcaccatggaa catgttagag | 1320 |
| gtgtgaggctt gcagaacacc gctggaggac ggacttgcgc ctatttatgtt gaaagaagat | 1380 |
| gcttggcagg caatgcgcata ctcactcggtt acctttatgtt ctcacatgtt gcatttcaa | 1440 |
| ggatatgtttt gtgtggatattt ctgcttagtgc ttaccacatgtt gtattctcag catgttaccc | 1500 |
| tcacactgtt gtgcgtatgaa actgttttgc gctgaggata tggctgtggaa attcctgtct | 1560 |
| agtttactgtt cagccctaat atgtacatata actgcaggatgtt ctacatataaa agctttttt | 1620 |
| tactgtatataat ttatgttttgc ttgtgggttcaaa caagtcatac ctgattaata tggatgcact | 1680 |
| ttgtttctatgtt tggttccctaa cccattgtctt gataaaatgac tttttctatgtt tggggatgtt | 1740 |
| acacttggatttt tggttccctctt tggatgtttt tttttttccctt ctcattgtgg gcttatttctt | 1800 |
| cattgtatgtt gtaggataaaatgaaatgtt ttttttttttgc ttttttttttgc ttttttttttgc | 1860 |
| gtttgcataatgtt tgggttagacc ttctccactc ctcacatgttccca acacatataatgtt gatgttgcac | 1920 |

agggggcata tggcaatcag aagccaaac tgcccttgag tctaagatgt gatgactttg 1980
 atgaaaacaca actgaaaaca tgagggacta tatccagtca cttgtagcca gtttcacagg 2040
 ccagctacag aattgtccaa acaaacatta tttctgactg caattttttt ccccaaattt 2100
 taaagcaatc cctggctta aatgacaagg cacctaccaa tggctttggg tcactgaaga 2160
 agctactacc atgagcctgt gcatagaatt ttaggatata aaaggatgaa tttctgtgac 2220
 tgccagtcag atcttaacag gttctgttg agccagaatc tggttcagat ccaagatgga 2280
 gaggaacact atggaaacctt cccaggtgac tttcagagca gttgtttcaa acacatcatt 2340
 gtccttttag gggaaaccagt ttttagaagg ttgtgaattt gtttttccac aaagcatgat 2400
 tatcttcctg gctgatccag gagaaaatta gaacagaaaa ataatggttg tggattttga 2460
 aacaaagcaa ggtaaagcct ttttttttc accttgcatt ggcaaaacta ccttttcag 2520

 gtttttaact tttgattcaa aagcatctt ccaataagga taaaatatcat atacatcg 2580
 atgaaaatat tgctatgaga taataagcca catatgaatg ttgtatacaa ctttagggtt 2640
 tacatttaat cctgaagtgt taccttcctt catgtctatt tacactatccatccat 2700
 taagtgggaa gggggctcc ttatatagtg cttcatcggtt aataagtcaa tacctgtt 2760
 tcctggatg ttcttttttgcattaaaaa acttcaaaat taaaaaaaaaaaaaaa 2820
 aaaaaaaaaa aaaaaaaaaa ag 2842

<210> 19

<211> 243

<212> PRT

<213> Homo sapiens <220>

<221> PEPTIDE

<222> (1)..(243)

<223> human Rspordin 2

<400> 19

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Met | Gln | Phe | Arg | Leu | Phe | Ser | Phe | Ala | Leu | Ile | Ile | Leu | Asn | Cys | Met |
| 1 | | | | 5 | | | | | 10 | | | | 15 | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Asp | Tyr | Ser | His | Cys | Gln | Gly | Asn | Arg | Trp | Arg | Arg | Ser | Lys | Arg | Ala |
| 20 | | | | | | | 25 | | | | | 30 | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Ser | Tyr | Val | Ser | Asn | Pro | Ile | Cys | Lys | Gly | Cys | Leu | Ser | Cys | Ser | Lys |
| 35 | | | | | | 40 | | | | | 45 | | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Asp | Asn | Gly | Cys | Ser | Arg | Cys | Gln | Gln | Lys | Leu | Phe | Phe | Phe | Leu | Arg |
| 50 | | | | | 55 | | | | 60 | | | | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Arg | Glu | Gly | Met | Arg | Gln | Tyr | Gly | Glu | Cys | Leu | His | Ser | Cys | Pro | Ser |
| 65 | | | | | | 70 | | 75 | | | | 80 | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Gly | Tyr | Tyr | Gly | His | Arg | Ala | Pro | Asp | Met | Asn | Arg | Cys | Ala | Arg | Cys |
| 85 | | | | | | | 90 | | | | | 95 | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Arg | Ile | Glu | Asn | Cys | Asp | Ser | Cys | Phe | Ser | Lys | Asp | Phe | Cys | Thr | Lys |
| 100 | | | | | | | 105 | | | | 110 | | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Cys | Lys | Val | Gly | Phe | Tyr | Leu | His | Arg | Gly | Arg | Cys | Phe | Asp | Glu | Cys |
| 115 | | | | | | 120 | | | | | 125 | | | | |

Pro Asp Gly Phe Ala Pro Leu Glu Glu Thr Met Glu Cys Val Glu Gly
 130 135 140

Cys Glu Val Gly His Trp Ser Glu Trp Gly Thr Cys Ser Arg Asn Asn
 145 150 155 160

Arg Thr Cys Gly Phe Lys Trp Gly Leu Glu Thr Arg Thr Arg Gln Ile
 165 170 175

Val Lys Lys Pro Val Lys Asp Thr Ile Pro Cys Pro Thr Ile Ala Glu
 180 185 190

Ser Arg Arg Cys Lys Met Thr Met Arg His Cys Pro Gly Gly Lys Arg
 195 200 205

Thr Pro Lys Ala Lys Glu Lys Arg Asn Lys Lys Lys Arg Lys Leu
 210 215 220

Ile Glu Arg Ala Gln Glu Gln His Ser Val Phe Leu Ala Thr Asp Arg
 225 230 235 240

Ala Asn Gln

<210> 20

<211> 2165

<212> DNA

<213> Homo sapiens

<220>

<221> gene

<222> (1)..(2165)

<223> human Rspordin 3

<400> 20

| | | | | | | |
|-------------|--------------|-------------|-------------|------------|-------------|-----|
| cgccggcgccc | cggcggtctcc | tggaaccccg | gttcgcggcg | atgccagcca | ccccagcgaa | 60 |
| gcccggcgca | ttcagtgttt | ggataatttg | aaagtacaat | agttggtttc | cctgtccacc | 120 |
| cgcggccactt | cgcttgcacat | cacagcacgc | ctatcgatg | tgagaggaga | agtcccgctg | 180 |
| ctcgccact | gtctatatac | gcctaacaacc | tacatataatt | ttaaaaacat | taaaatataat | 240 |
| taacaatcaa | aagaaagagg | agaaaggaag | ggaagcatta | ctgggttact | atgcacttgc | 300 |
| gactgatttc | ttggcttttt | atcattttga | actttatgga | atacatggc | agccaaaacg | 360 |
| cctccgggg | aaggcgccag | cgaagaatgc | atcctaacgt | tagtcaaggc | tgccaaggag | 420 |
| gctgtcaac | atgctcagat | tacaatggat | gtttgtcatg | taagcccaga | ctatttttg | 480 |
| ctctggaaag | aattggcatg | aagcagattg | gagttatgtct | ctcttcatgt | ccaaagtggat | 540 |
| attatggaaac | tcgatatatcca | gatataaata | agtgtacaaa | atgcaaagct | gactgtgata | 600 |
| cctgtttcaa | caaaaatttc | tgcacaaaat | gtaaaagtgg | attttactta | caccttgaa | 660 |
| agtgccttga | caattggcca | gaagggttgg | aagccaacaa | ccatactatg | gagtgtgtca | 720 |
| gtatttgca | ctgtgaggtc | agtgaatgga | atccttggag | tccatgcacg | aagaaggaa | 780 |
| aaacatgtgg | cttcaaaaga | gggactgaaa | cacgggtccg | agaaataata | cagcatcctt | 840 |
| cagcaaagg | taacctgtgt | cccccaacaa | atgagacaag | aaagtgtaca | gtgcaaaggaa | 900 |

| | | | | | | |
|------------|-------------|-------------|-------------|-------------|-------------|------|
| agaagtgtca | gaagggagaa | cgaggaaaaa | aaggaaggga | gaggaaaaga | aaaaaaccta | 960 |
| ataaaggaga | aagtaaagaa | gcaatacctg | acagcaaaag | tctggaatcc | agcaaagaaa | 1020 |
| tcccagagca | acgagaaaac | aaacagcagc | agaagaagcg | aaaagtccaa | gataaacaga | 1080 |
| aatcggtatc | agtcagcact | gtacactaga | gggttccatg | agattattgt | agactcatga | 1140 |
| tgctgctatc | tcaccagat | gccaggaca | ggtgctctag | ccattaggac | cacaaatgga | 1200 |
| catgtcagtt | attgctctgt | ctaaacaaca | ttcccagtag | ttgctatatt | cttcatacaa | 1260 |
| gcatagttaa | caacaaagag | ccaaaagatc | aaagaaggga | tacttcaga | tggttgtctt | 1320 |
| gtgtgcttct | ctgcattttt | aaaagacaag | acattcttg | acatattatc | aataggctat | 1380 |
| aagatgtaac | aacgaaatga | tgacatctgg | agaagaaaca | tctttcctt | ataaaaatgt | 1440 |
| gtttcaagc | tgttgtttta | agaagaaaaa | gatagttctg | caaattcaaa | gatacagtat | 1500 |
| cccttcaaaa | caaataaggag | ttcagggaaag | agaaacatcc | ttcaaaggac | agtgttgtt | 1560 |
| tgaccgggag | atctagagag | tgctcagaat | tagggcctgg | catttggaaat | cacaggattt | 1620 |
| atcatcacag | aaacaactgt | tttaagatta | gttccatcac | tctcatctg | tatttttata | 1680 |
| agaaacacaa | gagtgcatac | cagaattgaa | tataccatat | gggattggag | aaagacaaaat | 1740 |
| gtggagaaa | tcatagagct | ggagactact | tttgtcttt | acaaaactgt | gaaggattgt | 1800 |
| ggtcacctgg | aacaggtctc | caatctatgt | tagcaactatg | tggctcagcc | tctgttaccc | 1860 |
| cttggattat | atatcaacct | gtaaacatgt | gcctgttaact | tacttccaaa | aacaaaatca | 1920 |
| tacttattag | aagaaaattc | tgattttata | gaaaaaaaaat | agagcaagga | gaatataaca | 1980 |
| tgtttgcaaa | gtcatgtgtt | ttctttctca | atgagggaaa | aacaattttt | ttacctgctt | 2040 |
| aatggtccac | ctggaactaa | aaggataact | attttctaac | aaggtatatac | tagtagggga | 2100 |
| gaaagccacc | acaataaata | tattgttaa | tagttttca | aaaaaaaaaa | aaaaaaaaaa | 2160 |
| aaaaaa | | | | | | 2165 |

<210> 21

<211> 272

<212> PRT

<213> Homo sapiens

<220>

<221> PEPTIDE

<222> (1)..(272)

<223> human Rspordin 3

<400> 21

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Met | His | Leu | Arg | Leu | Ile | Ser | Trp | Leu | Phe | Ile | Ile | Leu | Asn | Phe | Met |
| 1 | | | | 5 | | | | 10 | | | | 15 | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Glu | Tyr | Ile | Gly | Ser | Gln | Asn | Ala | Ser | Arg | Gly | Arg | Arg | Gln | Arg | Arg |
| 20 | | | | | 25 | | | | | | | | 30 | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Met | His | Pro | Asn | Val | Ser | Gln | Gly | Cys | Gln | Gly | Gly | Cys | Ala | Thr | Cys |
| 35 | | | | | 40 | | | | | | | 45 | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Ser | Asp | Tyr | Asn | Gly | Cys | Leu | Ser | Cys | Lys | Pro | Arg | Leu | Phe | Phe | Ala |
| 50 | | | | | 55 | | | | | 60 | | | | | |

Leu Glu Arg Ile Gly Met Lys Gln Ile Gly Val Cys Leu Ser Ser Cys
 65 70 75 80

Pro Ser Gly Tyr Tyr Gly Thr Arg Tyr Pro Asp Ile Asn Lys Cys Thr
 85 90 95

Lys Cys Lys Ala Asp Cys Asp Thr Cys Phe Asn Lys Asn Phe Cys Thr
 100 105 110

Lys Cys Lys Ser Gly Phe Tyr Leu His Leu Gly Lys Cys Leu Asp Asn
 115 120 125

Cys Pro Glu Gly Leu Glu Ala Asn Asn His Thr Met Glu Cys Val Ser
 130 135 140

Ile Val His Cys Glu Val Ser Glu Trp Asn Pro Trp Ser Pro Cys Thr
 145 150 155 160

Lys Lys Gly Lys Thr Cys Gly Phe Lys Arg Gly Thr Glu Thr Arg Val
 165 170 175

Arg Glu Ile Ile Gln His Pro Ser Ala Lys Gly Asn Leu Cys Pro Pro
 180 185 190

Thr Asn Glu Thr Arg Lys Cys Thr Val Gln Arg Lys Lys Cys Gln Lys
 195 200 205

Gly Glu Arg Gly Lys Lys Gly Arg Glu Arg Lys Arg Lys Lys Pro Asn
 210 215 220

Lys Gly Glu Ser Lys Glu Ala Ile Pro Asp Ser Lys Ser Leu Glu Ser
 225 230 235 240

Ser Lys Glu Ile Pro Glu Gln Arg Glu Asn Lys Gln Gln Gln Lys Lys
 245 250 255

Arg Lys Val Gln Asp Lys Gln Lys Ser Val Ser Val Ser Thr Val His
 260 265 270

<210> 22

<211> 2722

<212> DNA

<213> Homo sapiens

<220>

<221> gene

<222> (1)..(2722)

<223> human Rspordin 4

<400> 22

| | | | | | | |
|------------|------------|-------------|------------|-------------|------------|-----|
| cacagcagcc | ccccgcggcc | ccgtgccgccc | gccgggacgt | ggggcccttg | ggccgtcgaa | 60 |
| ccgcctgggg | agcgccagcc | cgatccggc | tgccccatg | cgggcgccac | tctgcctgct | 120 |
| cctgctcgtc | ccccacgccc | tggacatgct | cgcctgaac | cgaaggaaaga | agcaagtggg | 180 |
| cactggcctg | gggggcaact | gcacaggctg | tatcatctgc | tcagaggaga | acggctgttc | 240 |

| | |
|-----------------------------------------------------------------------|------|
| cacctgccag cagaggctct tcctgttcat ccgcgggaa ggcatccgcc | 300 |
| gtgcctgcac gactgtcccc ctgggtactt cggcatccgc ggccaggagg tcaacaggtg | 360 |
| caaaaaatgt ggggccactt gtgagagctg cttcagccag gacttctgca tccggtgcaa | 420 |
| gaggcagttt tacttgtaca aggggaagtg tctgcccacc tgcccgccgg gcaactttggc | 480 |
| ccaccagaac acacgggagt gccaggggaa gtgtgaactg ggtccctggg gccggctggag | 540 |
| ccctgcaca cacaatggaa agacctgcgg ctcggcttgg ggcctggaga gccgggtacg | 600 |
| agaggctggc cgggctggc atgaggaggc agccacctgc caggtgcttt ctgagtcaag | 660 |
| gaaatgtccc atccagaggc cctgcccagg agagaggagc cccggccaga agaaggcag | 720 |
| gaaggaccgg cgccccacgca aggacaggaa gctggaccgc aggctggacg tgaggccgcg | 780 |
| ccagcccgcc ctgcagccct gaccgcggc tctcccgact ctctggctt agtcctcgcc | 840 |
| ccctgcacac ctccctctgc tccttctctt cctctctct tactctttctt cctctgtctt | 900 |
| ctccatttgt cctctcttgc tttccaccct tctatcattt ttctgtcagt ctacattccc | 960 |
| tttctttttc ttttttattt ctttttatttcc ttccacctcc attctctctt cctttctccc | 1020 |
| tccttccttc ctttccttcc ttttctttctt cacttatctt ttatcttccc ttttctttctt | 1080 |
| tcctgtgttt cttcctgtcc ttcacccat ctttctcttctt ctccctcttc ttgtctccct | 1140 |
| ctcacacacaca cttaagagg gaccatgagc ctgtgccctc ccctgcagct ttctctatct | 1200 |
| acaacttaaa gaaagcaaac atctttttcc aggccttcc ctgaccccat ctttgcagag | 1260 |
| aaagggtttc cagaggcaca agctggaca cagcacaggt gaatctgaa ggccctgttt | 1320 |
| ctgctctggg ggaggctcca ggaccctgag ctgtgagcac ctggttctct ggacagtccc | 1380 |
| cagaggccat ttccacagcc ttcaaggccacc agccaccccg aggagctggc tggacaaggc | 1440 |
| tccaggcctt ccagaggcct ggcttgaca cctcccccag ctggccgtgg agggtcacaa | 1500 |
| cctggcctct ggggtggcag ccagccctgg agggcatctt ctgcaagctg cctgccaccc | 1560 |
| tcatcggcac tcccccacag gcctccctctt catgggttcc atgccccttt ttcccaagcc | 1620 |
| ggatcaggtg agctgtcaact gctggggat ccacctgccc agcccagaag aggccactga | 1680 |
| aacggaaagg aaagctgaga ttatccagca gctctgttcc ccacccatc gcttcctgccc | 1740 |
| catgtgggaa aacaggtctg agaaggaagg ggcttgccca gggtcacaca ggaagccttc | 1800 |
| aggctctgct tctgcctgat ggctctgctc agcacattca cggtgagag gagaattttgg | 1860 |
| gggtcaatttgg agggggggaaa tgttagggat tgggggtgg gagcaaggga agatccgtgc | 1920 |
| actcgtccac acccaccacc acactcgctg acacccaccc ccacacgctg acacccaccc | 1980 |
| ccacacttgc ccacacccat caccgcactc gcccacaccc accaccacac tgccccacac | 2040 |
| ccaccacccac actccccccac acccaccacc acactcgccc acacccacca ccagtgactt | 2100 |
| gagcatctgt gtttcgtgt gacgccccctc gcccctaggca ggaacgcacgc tgggaggagt | 2160 |
| ctccaggtca gacccagctt ggaagcaagt ctgtcctcac tgcctatctt tctgccatca | 2220 |
| taacacccccc ttccctgtctt gctcccccggaa atcctcagaa acgggatttg tatttgcgt | 2280 |
| gactgggtgg cctgaacacg tagggctccg tgactggac aggaatggc aggagaagca | 2340 |
| agagtcggag ctccaaggggg cccaggggtg gcctggggaa ggaagatggt cagcaggctg | 2400 |
| ggggagagggc tctaggtgtt gaaatattac attcccgacc ccaagagagc acccaccctc | 2460 |
| agacctgccc tccacctggc agctggggag ccctggctg aacccccc tccacccagg | 2520 |
| ccacccctctt ctctgacttcc cctgctctca cctcccccggag aacagctaga gccccctctt | 2580 |
| ccgcctggcc aggccaccag cttcttttctt gcaaacgttt gtgcctctga aatgctccgt | 2640 |

tgttattgtt tcaagaccct aactttttt taaaacttc ttaataaagg gaaaagaaac 2700
 ttgtaaaaaaaaaaaaaa aa 2722

<210> 23

<211> 234

<212> PRT

<213> Homo sapiens

<220>

<221> PEPTIDE

<222> (1)..(234)

<223> human Rspndin 4

<400> 23

Met Arg Ala Pro Leu Cys Leu Leu Leu Val Ala His Ala Val Asp
 1 5 10 15

Met Leu Ala Leu Asn Arg Arg Lys Lys Gln Val Gly Thr Gly Leu Gly
 20 25 30

Gly Asn Cys Thr Gly Cys Ile Ile Cys Ser Glu Glu Asn Gly Cys Ser
 35 40 45

Thr Cys Gln Gln Arg Leu Phe Leu Phe Ile Arg Arg Glu Gly Ile Arg
 50 55 60

Gln Tyr Gly Lys Cys Leu His Asp Cys Pro Pro Gly Tyr Phe Gly Ile
 65 70 75 80

Arg Gly Gln Glu Val Asn Arg Cys Lys Lys Cys Gly Ala Thr Cys Glu
 85 90 95

Ser Cys Phe Ser Gln Asp Phe Cys Ile Arg Cys Lys Arg Gln Phe Tyr
 100 105 110

Leu Tyr Lys Gly Lys Cys Leu Pro Thr Cys Pro Pro Gly Thr Leu Ala
 115 120 125

His Gln Asn Thr Arg Glu Cys Gln Gly Glu Cys Glu Leu Gly Pro Trp
 130 135 140

Gly Gly Trp Ser Pro Cys Thr His Asn Gly Lys Thr Cys Gly Ser Ala
 145 150 155 160

Trp Gly Leu Glu Ser Arg Val Arg Glu Ala Gly Arg Ala Gly His Glu
 165 170 175

Glu Ala Ala Thr Cys Gln Val Leu Ser Glu Ser Arg Lys Cys Pro Ile
 180 185 190

Gln Arg Pro Cys Pro Gly Glu Arg Ser Pro Gly Gln Lys Lys Gly Arg
 195 200 205

Lys Asp Arg Arg Pro Arg Lys Asp Arg Lys Leu Asp Arg Arg Leu Asp
 210 215 220

Val Asn Pro Arg Gln Pro Gly Leu Gln Pro

225 230

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- WO0177169A [0002]
- WO0107611A [0002]
- US20060149049A [0002]
- US20050059073A [0002]
- US2005054829A [0002]
- WO2005040418A [0002] [0015] [0020]
- US4946778A [0077]
- EP06022070A [0133]

Non-patent literature cited in the description

- **CHEN** et al. Mol. Biol. Rep., 2002, vol. 29, 287-292 [0002]
- **KAMATA** et al. Biochim. Biophys. Acta., 2004, vol. 1676, 51-62 [0002] [0003]
- **KAZANSKAYA** et al. Dev. Cell, 2004, vol. 7, 525-534 [0002] [0003] [0003] [0017] [0123]
- **KIM** et al. Science, 2005, vol. 309, 1256-1259 [0002]
- **KIM** et al. Cell Cycle, 2006, vol. 5, 23-26 [0002]
- **NAM** et al. J. Biol. Chem., 2006, vol. 281, 13247-13257 [0002]
- **KIM** et al. Science, 2005, vol. 309, 1256-9 [0003]
- **AOKI** et al. Dev Biol., 2007, vol. 301, 1218-26 [0003]
- **FERRARA** Oncology, 2005, vol. 3, 11-6 [0005]
- **ROSEN** Oncologist, 2005, vol. 10, 382-91 [0005]
- **MEAD** et al. Development, 1998, vol. 125, 2611-2620 [0013]
- **DEVIC** et al. Mech Dev., 1996, vol. 59, 129-40 [0013]
- **CARUTHERS** et al. Nuc. Acids Res. Symp. Ser., 1980, vol. 7, 215-233 [0055]

- **CREAHORNN**Nuc. Acids Res., vol. 9, 102331- [0055]
- **MATTEUCCICARUTHERS**Tetrahedron Letters, 1980, vol. 21, 719- [0055]
- **CHOWKEMPEN**Nuc. Acids Res., 1981, vol. 9, 122807-2817 [0055]
- **CREIGHTON**Proteins Structures And Molecular PrinciplesW. H. Freeman and Co.1983000050-60 [0055]
- **CREIGHTON**Proteins, Structures and Molecular PrinciplesW. H. Freeman and Co.1983000034-49 [0055]
- **MANIATIS et al.**Molecular Cloning A Laboratory ManualCold Spring Harbor Laboratory19890000 [0057]
- **AUSUBEL et al.**Current Protocols in Molecular BiologyGreene Publishing Associates and Wiley Interscience19890000 [0057]
- **KOHLERMILSTEIN**Nature, 1975, vol. 256, 495-497 [0077]
- **KOSBOR et al.**Immunology Today, 1983, vol. 4, 72- [0077]
- **COTE et al.**Proc. Natl. Acad. Sci., 1983, vol. 80, 2026-2030 [0077]
- **COLE et al.**Monoclonal Antibodies and Cancer TherapyAlan R. Liss, Inc.1985000077-96 [0077]
- **MORRISON et al.**Proc. Natl. Acad. Sci., 1984, vol. 81, 6851-6855 [0077]
- **NEUBERGER et al.**Nature, 1984, vol. 312, 604-608 [0077]
- **TAKEDA et al.**Nature, 1985, vol. 314, 452-454 [0077]
- **HUSE et al.**Science, 1989, vol. 246, 1275-1281 [0078]
- **FERRARA, N.HENZEL, W. J.**Biochem. Biophys. Res. Comm., 1989, vol. 161, 851-858 [0086]
- Remington's Pharmaceutical SciencesMack Publishing Co. [0095]
- **FINGL et al.**The Pharmacological Basis of Therapeutics197500001- [0109]
- **DEL BARCO et al.**Genes Dev., 2003, vol. 17, 2239-2244 [0120]
- **GAWANTKA et al.**EMBO J., 1995, vol. 14, 6268-79 [0120] [0120] [0122]
- **BRADLEY et al.**Development, 1996, vol. 122, 2739-2750 [0120]

Patentkrav

- 1.** Anvendelse af et Rspordin2- eller 3-polypeptid eller en Rspordin2- eller 3-nukleinsyre i fremstillingen af et medikament til behandlingen af en patologisk tilstand der forbedres ved fremmelse af angiogenese og/eller vaskulogenese ved 5 fremmelse af angiogenese og/eller vaskulogenese.
- 2.** Anvendelsen ifølge krav 1 til fremmelse af sårheling, vævs- og organregenerering eller -udvikling, fosterudvikling og/eller forplantningsprocesser, eller til inhiberingen af degenerative processer, især vaskulodegenerative 10 processer såsom iskæmiske processer såsom kritisk ekstremitetsiskæmi, hjerneiskæmi eller iskæmisk hjertesygdom.
- 3.** Anvendelse af en Rspordin2- eller 3-antagonist i fremstillingen af et medikament til behandlingen af en patologisk tilstand der forbedres ved inhibering 15 af angiogenese og/eller vaskulogenese ved inhibering af angiogenese og/eller vaskulogenese, hvor antagonisten af Rspordin2 eller 3 er et anti-Rspordin 2- eller anti-Rspordin3-antistof eller et antisense-molekyle eller siRNA-molekyle.
- 4.** Anvendelsen ifølge krav 3, hvor antagonisten af Rspordin2 eller 3 er et anti- 20 Rspordin 2-antistof.
- 5.** Anvendelsen ifølge krav 3, hvor antagonisten af Rspordin2 eller 3 er et anti- Rspordin 3-antistof.
- 6.** Anvendelsen ifølge et hvilket som helst af kravene 4-5, hvor antistoffet er et 25 rekombinant polyklonalt, monoklonalt, kimært, humaniseret, eller enkelt-kædet antistof eller fragment deraf.
- 7.** Anvendelsen ifølge et hvilket som helst af kravene 4-6, hvor antistoffet er et 30 monoklonalt antistof.
- 8.** Anvendelsen ifølge et hvilket som helst af kravene 4-6, hvor antistoffet er et humaniseret antistof.

2

9. Anvendelsen ifølge et hvilket som helst af kravene 3-8 til behandlingen af tumorvækst, især fast tumorvækst, rheumatoid arthritis, atherosclerose, stenose, restenose, retinopati, makulær degeneration eller psoriasis.

5

10

DRAWINGS

Fig. 1




Fig. 2




Fig. 3




Figure 4



Fig. 5




Fig. 6



Figure 7




Figure 8




Fig. 9




Figure 10




Fig. 11

